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Abstract 
 
Cyanide is a metabolic poison that inhibits utilization of oxygen to form 
ATP. The consequences of acute cyanide exposure are severe: toxic doses 
result in loss of consciousness, cardio and respiratory failure, hypoxic brain 
injury, and dose-dependent death from within minutes to hours. In a mass 
casualty scenario such as an industrial accident or terrorist attack, currently 
available cyanide antidotes would leave many victims untreated in the short time 
available for successful medical countermeasure administration. 
 Therefore, there is a need for rapidly acting antidotes that can be quickly 
administered to large numbers of people who may be unconscious. Sulfanegen, 
a novel preclinical cyanide antidote, is being developed to meet this need. 
Sulfanegen is administered by intramuscular injection (IM), which has the 
advantages of requiring minimal training for first responders, as well as the 
potential for rapid antidotal administration to many affected people.  
Due to ethical issues involved with testing cyanide antidotes in human 
subjects, sulfanegen cannot go through the normal clinical trial path to drug 
approval. However, the FDA has published guidelines for evidence needed to 
gain approval under the “Animal Rule”, which this thesis attempts to address. 
The “Animal Rule” allows for new drug approval if the following conditions are 
met: 1) Effective in more than one animal model with a response predictive for 
humans, 2) Pharmacokinetics understood well enough to determine effective 
dose, and 3) A well-understood mechanism of action and pathology of the 
disease.  
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We first elucidated the animal models predictive for human efficacy testing 
by MST species comparison of the blood of many common laboratory animals. 
Based on this preliminary screen, species closest to that of humans were chosen 
to characterize the MST activities in metabolically active tissues. Using those 
findings, we determined swine were not an appropriate model for predicting 
efficacy in humans, while murine and rabbit models were appropriate. 
Next, we developed an isocratic UV-VIS HPLC method for characterizing 
the pharmacokinetics of sulfanegen in humans. Pre-column derivitization with 
NEM prevented the reformation of the 3-mercaptopyruvate (3MP) dimer and 
allowed for chromatographic detection. Moreover, this method is easily modified 
for applications to quality control, being able to separate sulfanegen from its 
precursor molecules and predicted decomposition products.  
Finally, we examined the potential secondary mechanisms of sulfanegen 
administration. MST catalyzed detoxification of cyanide to thiocyanate is the 
primary mechanism of action, but secondary mechanisms involving 3MP alone or 
in conjunction with MST contribute to the overall efficacy of sulfanegen. 3MP was 
found to be a potent antioxidant, capable of quenching cyanide induced ROS. 
Additionally, H2S generation by MST was confirmed after sulfanegen 
administration. Although it was confirmed that cyanohydrin formation was 
occurring, this probably does not contribute to reversing cyanide-induced 
cytochrome c oxidase inhibition. 
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1. Introduction 
Chemical threats such as cyanide pose an ever-increasing risk to human 
life due to their relative ease of accessibility and potential to cause mass 
casualties. The National Institutes of Health (NIH) Countermeasures Against 
Chemical Threats (CounterACT) Program classifies cyanide as a “higher priority 
threat”, highlighting the need for new antidotal developments. This chapter will 
cover cyanide’s history, symptoms, mechanisms of toxicity, as well as both 
current and future approaches to antagonism of toxicity. The goals of projects 
covered in the following chapters derive from unique characterization hurdles 
involved in approval of chemical countermeasures. The focus is on studies 
necessary for the clinical translation of sulfanegen, a next generation pre-clinical 
cyanide antidote. The studies include elucidation and validation of secondary 
mechanisms of action, justification of species chosen for efficacy studies, 
analytical method development suitable for pharmacokinetic studies, and 
examining the possibility of extension of this and similar compounds to other 
clinical uses.  
1.1 History of Cyanide 
Cyanide is an archetypal poison, whose use is documented throughout 
human history.1 Historical poisonings usually occurred by means of plants 
containing cyanogenic glycosides such as almonds, cherry laurel, and cassava. 
Both the Egyptians and Romans used cyanogenic compounds in executions 
(peach pits and cherry laurel respectively).1 The first written descriptions of 
cyanide poisoning dates back to Wepfer’s use of almond extract in 1679, and 
Maddern’s canine toxicity demonstrations in 1731 using the extracts of cherry 
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laurel.2 However, the causative agent for the toxicity was not isolated until 1782 
by Carl Windhelm Scheele.3 Scheele heated Prussian blue with sulfuric acid, 
generating hydrogen cyanide (HCN), which he named prussic acid.3  
1.2 Cyanide Exposure Scenarios 
1.2.1 Industrial Accidents 
Today, cyanide exposure can occur as a result of industrial accidents, 
smoke inhalation, naturally occurring sources, or deliberate release as an agent 
of war/terror. In the United States alone, about 2 billion pounds of cyanide are 
produced annually for broad uses in industry, including: the extraction of 
gold/silver in mining, metallurgy, pesticides, electroplating, the production of 
textiles, and in the aquatics industry for stunning fish prior to capture.4–6 
Therefore, an accidental exposure during either the use or transportation of 
cyanide is major cause for concern. These worries were realized in 1984 when 
gaseous methyl isocyanate and cyanide containing combustion products were 
released during a fire at a pesticide plant in the densely populated city of Bhopal, 
India resulting in 1,800-5,000 deaths and up to 200,000 injuries.7 
1.2.2 Smoke Inhalation 
 Due to the use of nitriles in the production of textiles and other goods, 
smoke inhalation is another source of cyanide exposure. Incomplete combustion 
of nitrogen containing organics prepared from the above nitriles can result in 
release of hydrogen cyanide. Thus, cyanide poisoning is often overlooked in 
cases of smoke inhalation toxicity.8–10 Combusting just 1 g of polyacrylonitrile, 
produces 1,500 ppm cyanide in a 15.6 L combustion chamber, and it has been 
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estimated just 2 kg of polyacrylonitrile is needed to produce toxic levels in the 
average sized living room.11 During a fire, any delay in escape caused by 
decreased visibility or impedance of exits prolongs the duration of exposure to 
toxic smoke, increasing the chance of fatalities. Baud et al compared the blood 
cyanide and carbon monoxide levels of smoke inhalation victims and found large 
differences between fatal and nonfatal fires.12 From 109 fire victims studied, 43 
had died, and the cyanide concentration in the blood of the fatalities was 116.4 
µM +/- 89.6, compared to 21.6 µM +/- 36.4 for those who had survived, and just 
5.0 µM +/- 5.5 for control samples from the general population. Carbon monoxide 
levels between the two groups were 2.8 mM +/- 2.0 for fatal incidents and 0.7 
mM +/- 0.7 for non-fatal incidents. While carbon monoxide levels also increased, 
some of the deceased had non-lethal levels of carbon monoxide, yet fatal levels 
of cyanide in the blood. It therefore follows that increased exposure to cyanide-
containing fumes decreases the chance for survival in the case of fires, and that 
both carbon monoxide and cyanide exposure contribute to fire deaths.12  
The importance of cyanide in smoke inhalation is highlighted by the Kiss 
nightclub fire disaster of 2013 in Brazil, which occurred during a crowded event. 
The incident ultimately left 242 dead and over 600 injured. The fire reportedly 
started when a member of the band lit a pyrotechnic device that ignited 
soundproofing material overhead releasing toxic cyanide-containing smoke. 
Officials reported that a lack of emergency exits contributed to the high fatality 
number.13 
	 5	
1.2.3 Naturally Occurring Cyanide 
 Cyanide has been detected throughout the universe in starbursts, and is 
released into the atmosphere via volcanoes.14–16 However, most naturally 
occurring sources of cyanide leading to accidental exposures are confined to the 
plant kingdom. There are over 2000 plant species that contain cyanogenic 
glycosides, which can generate HCN when cells containing them are 
ruptured.17,18 This is likely a defense mechanism in that herbivore consumption of 
these plants can cause illness or even death.19 Such toxicity is well-documented 
in livestock, especially cattle.20,21 
1.2.4 Agent of War 
 Deliberate use of weaponized cyanide was not employed on the battlefield 
in modern times until World War I (WWI). The development of trench warfare at 
the first battle of the Aisne in 1914 gave the tactical advantage to defenders, and 
the frontlines ground to a halt with each side digging in.22 The war of maneuver 
that contemporaries of the day believed would end quickly had transformed into a 
stalemate. To overcome this stalemate, both sides began innovating outside of 
the norms of conventional warfare. The Hague convention of 1899 banned the 
use of projectiles to spread chemical weapons.23,24 However, German forces 
were the first to break this convention, with the use of chlorine gas in the second 
battle of the Ypres in April 1915. Chlorine gas (498 tons) was discharged from 
20,730 cylinders.22,25 German leadership argued this did not violate the Hague 
conventions, as they simply opened canisters of gas and let the wind blow the 
gas to the enemy lines, rather than deliver it via munitions.26 It is important to 
note many countries were considering chemical warfare before that point, with 
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US patents being filed for incendiary devices containing hydrogen cyanide and 
the UK considering the use of sulfur dioxide as early as 1914.27,28 After that 
incident, gas attacks became more commonly used by both sides, with some 
calling WWI the “chemists war”.29,30 Unlike other conventional weapons, both 
sides developed and deployed effective countermeasures in the form of charcoal 
containing gas masks. French forces started experimenting with HCN containing 
artillery shells in 1916, partly due to HCN’s ability to pass through these gas 
masks. Eventually, 4,000 tons were manufactured for war.31 However, HCN’s 
high volatility limits its usefulness in trench warfare as it disperses too rapidly to 
be effective in open-air. As a result, both the French and Austrians experimented 
with cyanogen chloride/bromide respectively, which had a cumulative effect and 
was more effective than HCN alone.22,25 
 Following WWI, the Geneva protocol was ratified in 1925, prohibiting the 
use of biological and chemical weapons in warfare.32 However, these laws would 
be tested again merely a decade later. During World War II (WWII), chemical 
weapons played a smaller role on the battlefield, partly due to the deterrent of 
both sides having large stockpiles of chemical weapons as well as the necessary 
protective equipment.  Between 1922 and 1945, the United States produced 500 
tons of HCN and 11,400 tons of cyanogen chloride.22,33 Meanwhile, Japan 
produced 255 tons of HCN from 1939 to 1945 and German production after 1944 
was 20 tons per month.22,34 However, Zyklon B, which was a commercially 
available pesticide containing HCN, was used by the Nazis in gas chambers to 
kill millions of civilians as well as enemy combatants in death camps. HCN was 
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detected on the walls of the gas chambers nearly 50 years later, demonstrating 
its extensive use.35 
 Following the great wars, cyanide use on battlefields declined, with the 
next reports of its use occurring in the 1980s when it was used during the Iran-
Iraq wars.36,37 However, declining use of cyanide in war has not been the end of 
cyanide’s deliberate release to impact human health.  
1.2.5 Use of Cyanide in Suicide, and Murders 
As cyanide availability increased due to its broad adaptation for 
applications in industry, incidents of cyanide related suicides, murder, and 
terrorism became more common. Possibly the best known example of cyanide’s 
role in suicide is the Jonestown mass suicide of 1978.38 Jim Jones was the 
leader of a cult known as “The Peoples Temple”, which relocated to Guyana in 
1974 after the tide of public perception began to turn against them. However, 
their troubles did not stop there, pressure from relatives back in the US 
eventually lead US representative Leo Ryan to visit Jonestown. Jones’ increasing 
paranoia about the potential for negative stories leading to persecution as a 
result of this visit lead him to order the assassination of Ryan. Knowing the 
backlash this action would cause, he convinced over 900 people to consume a 
Flavor-Aid drink laced with cyanide, among other intoxicants.38 
Deliberate use of cyanide in murders has been known throughout history, 
and is still relevant today.  Recent examples of cyanide being employed in 
murder are the Chicago Tylenol murders of 1980s, which killed 7 people and 
resulted from cyanide laced Tylenol packages being placed on store shelves and 
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sold to consumers.39 This incident lead to consumer protection reform and the 
resulting tamper-resistant packaging laws. The perpetrator behind these 
poisonings was never caught.  More recent examples of deliberate cyanide 
poisonings in the news are the deaths of potential Whitey Bulger witness 
Stephen Rakes in 2013, million dollar Chicago lottery winner Urooj Khan in 2012, 
and University of Pittsburgh neuroscientist Autumn Klein in 2013.40–42 
1.2.6 Agent of Terror 
Cyanide as an agent of terror is an increasing threat. Compared to its relative 
ineffectiveness on the battlefield due to its volatility, cyanide’s efficacy as a 
weapon is greatly increased in enclosed spaces. Additionally, the large quantities 
of cyanide used in industry provide relatively easy access compared to other 
chemical or biological threats of interest. This threat materialized in 2002, when a 
commercial truck carrying nearly 8 tons of sodium cyanide in Mexico was 
stolen.43 To this day, 6 of 96 barrels remain unaccounted for after the robbery.44 
In another example, US counterterrorism forces had credible threats of Al-
Qaeda’s intent in 2013 to release cyanide into the New York subway system. The 
attack was reportedly called off by Al-Qaeda leadership for unknown reasons.45 
These plans were reminiscent of the Tokyo subway terror attacks of 1995, where 
members of the Aum Shinrikyo cult used sarin, resulting in 12 deaths and over 
5,000 injuries.46 Other examples include the 2002 indictment of Joseph Konopk 
(“Dr. Chaos”) for storing cyanide in the Chicago subway system, and the 2008 
arrest Jeffrey Detrixhe for attempting to sell 100 pounds of sodium cyanide to a 
member of the Aryan Brotherhood during an FBI sting operation.47,48 Detrixhe 
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reportedly bragged the amount was enough to “kill a city”.48 Thus, the use of 
cyanide in terrorist attacks clearly remains a genuine threat.  
1.3 Incidence Rates 
 Cyanide poisoning occurrences in the United States are tracked by the 
American Association of Poison Control Center’s National Poison Data System 
(NPDS). Data included in the annual reports from 2010-2015 are given in Table 
1. The number of case mentions, single exposures, intentionality of the exposure, 
hospital visits, and deaths are reported therein.49–54 
Year Cases Single 
Exposures 
Accidental 
Exposures 
Intentional 
Exposures 
Hospital 
Visits 
Deaths 
2015 205 143 107 14 86 3 
2014 245 187 126 19 134 9 
2013 358 294 244 18 103 8 
2012 202 148 103 22 85 7 
2011 246 177 133 14 97 3 
2010 225 145 103 18 89 8 
Total 1481 1094 921 105 594 38 
Table 1. Cyanide exposures in the United States from 20010 to 2015 as reported 
by the NPDS. 49–54 
 
 Reports of unintentional exposures to cyanide outnumber those of 
intentional exposures; this contrasts with the perception of cyanide being 
primarily used in high profile suicides that are well known in American culture. 
Many of these unintentional exposures result from small-scale accidents during 
the use of cyanide in industry or cyanide-containing smoke inhalation during 
fires. Overall, the relatively few cases of cyanide exposure each year are no 
excuse for a lack of preparedness. For the most part, the current antidotes 
(covered in section 1.8) perform adequately in a setting where few are exposed 
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provided a rapid medical response (shortcomings of current antidotes are 
covered in section 1.9). However, current readiness is inadequate for mass 
casualty exposure, where stockpiles of available antidote, properly trained 
medical personnel, and limitations of the antidotes themselves play a large factor 
between life and death for those exposed.  
1.4 Preparedness 
The risk of cyanide toxicity in smoke inhalation, and industrial/laboratory 
use means emergency response personnel need rapidly acting medical 
countermeasures. RTI International published a rare look into the national 
cyanide disaster readiness in 2006 that detailed advanced life support (ALS) 
preparedness and perceived threat levels in the US post-September 11, 2001.  
Cyanide’s toxicity is dose dependent and can cause death within minutes 
to hours (mechanisms of toxicity covered in section 1.5 below), making 
availability an antidotes paramount to saving lives. However, the results from this 
survey showed that in 76% of standard emergency vehicles no cyanide antidote 
was available. Additionally, cyanide antidotes were ranked as low importance 
compared to other supplies on the vehicle by 28% of ALS providers. The average 
number of antidote kits available in hospitals was 25.7 kits per 100,000 people.  
Approximately a third (32.1%) of providers surveyed did not have access to a 
larger antidote cache as part of a disaster readiness plan, and 31.7 % did not 
know if they had such a cache available. More than two-thirds (68.8%) of high 
cyanide interest areas reported access to large caches of antidotes available in 1 
hour or less.55 However, these larger caches are unlikely to be of much use in 
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response to deliberate release of cyanide in a confined area, as the therapeutic 
window necessitates rapid antidote administration. 
Additionally, access to antidotes is only part of the preparedness problem. 
Another crucial area for disaster readiness is availability of trained medical 
personnel. Only 16% of ALS personnel in the RTI International study had 
experience administering a cyanide antidote; exposing another pain point in the 
chain of successful countermeasure deployment.55  
1.5 Mechanisms of Toxicity 
 Cyanide is classified as a metabolic poison. Its primary mechanism of 
toxicity is attributed to cytochrome c oxidase inhibition.56 Cytochrome c oxidase is 
the terminal electron acceptor in the electron transport chain. The electron 
transport chain utilizes NADH and FADH2, the end products of the citric acid 
cycle, to pump protons across the inner mitochondrial membrane, forming a 
proton gradient. It accomplishes this using four complexes (I-IV), coenzyme Q, 
and cytochrome C. Electrons donated from NADH and FADH2 move through the 
complexes by means of redox chemistry, releasing the energy needed at each 
step to move protons from inside the inner membrane to the intermembrane 
space. Ubiquinone (coenzyme Q) receives electrons from complex I & II 
(donated by NADH and FADH2 respectively) and passes them onto Complex III. 
Electron transport terminates at complex IV, also known as cytochrome C 
oxidase, where oxygen is the ultimate electron recipient, forming water.  The 
proton gradient is then employed by ATP synthase which pumps protons from 
the intermembrane space across the inner membrane to produce ATP (Figure 
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1). Cyanide inhibits cytochrome C oxidase by binding to the reduced form of 
cytochrome a3 preventing oxidative phosphorylation.57 Cells can temporarily 
adapt to this inhibition by switching ATP production to the less productive 
glycolysis pathway, but buildup of the resulting lactic acid leads to metabolic 
acidosis and symptoms of toxicity (covered in section 1.6).56  
In addition to loss of ATP production, cyanide also leads to production of 
reactive oxygen species (ROS) and results in oxidative stress and lipid 
peroxidation.58,59 This ROS generation is dependent on NMDA receptor 
activation and Ca2+ influx.59 Cyanide also inhibits other heme-containing 
enzymes, some of which contribute to the antioxidant defense system such as 
superoxide dismutase and glutathione reductase.58 
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Figure 1. The electron transport chain and ATP synthase. Electrons travel from 
complex I through complex IV, pumping hydrogen ions across the inner 
mitochondrial membrane, which ATP synthase uses to drive ATP. [Image 
modified from60. No permission required for educational use (CC BY-NC-SA 4.0)]	 
 
1.6 Symptoms of Cyanide Exposure 
1.6.1 Acute Symptoms 
 Symptoms of cyanide poisoning are dose dependent, and ultimately stem 
from biological mechanisms of toxicity in preventing oxygen utilization  (Lethal 
doses of cyanide in humans are 1.52 mg/kg orally or 500 ppm over 10 minutes 
via inhalation).5 Due to inhibition of aerobic respiration, the body attempts to 
increase oxygen levels. As a result, the symptoms are very similar to tissue 
hypoxia, with the noted exception of oxygenated venous blood in cyanide-
poisoned persons. Metabolically active tissues such as the central nervous 
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system (CNS) and heart are the most sensitive due to their high oxygen demand. 
Cyanide poisoning presents clinically in hyperventilation, tachycardia, nausea, 
dizziness and metabolic acidosis. In severe cases apnea or hypopnea, 
cardiopulmonary failure, loss of consciousness, and death follow.5 The above 
symptoms likely result from the cardiac and neuronal tissues’ aforementioned 
greater sensitivity to cyanide.5 An almond scented breath has also been 
described, however this is of limited diagnostic utility; the odor is faint and only a 
fraction of the population can detect cyanide via smell, with estimates of 20-30% 
of the population failing to detect it.61 Death is dose dependent and occurs within 
minutes to hours. Thus, a rapid response to cyanide exposure is paramount to 
saving lives.  
1.6.2 Chronic Symptoms 
Patients who survive high dose cyanide intoxication (usually resulting from 
failed suicide attempts) are relatively rare, but those who do survive often 
develop a Parkinsons-like set of symptoms. Published case studies following 
survivors are rare, but do exist.36,62–68 These symptoms do not respond to 
standard Parkinson’s therapies such as L-dopamine supplementation, 
illuminating a key difference in pathology, even in the presence of similar 
symptoms. 36,62–68 
In contrast to sub-lethal acute poisonings, chronic sub-lethal ingestion of 
cyanide, usually in the form of cyanogenic glycosides, can lead to a condition 
known as konzo.36,69 Konzo is a poorly understood and troubling condition 
resulting in loss of visual acuity and paraparesis, or partial paralysis of the lower 
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limbs. Symptoms set in within 1 day for 90% of cases and the disease typically 
results in chronic disabling paraparesis.70–73 Currently, prevention is the only 
known treatment for this debilitating disease.74 The cassava root is a 
carbohydrate staple in the diets of many central African nations and the Congos.  
Cassava contains the cyanogenic compound linamarin. During times of drought, 
people of the Congo depend heavily on this crop for sustenance, and its 
consumption when improperly prepared is linked with konzo.75 Proper 
preparation of the cassava plant by boiling breaks down the linamarin and 
prevents ingestion of cyanogenic compounds. There is also emerging interest in 
cyanide antidotes taken concurrently with cassava-containing meals, as 
administration of antidote with potential sources cyanide ingestion may prevent 
the onset of konzo.  
1.7 Endogenous Detoxification Pathways 
 The persistence of cyanide in the environment has applied evolutionary 
pressure on aerobic organisms for mechanisms of defense against it. The key 
pathways for mammalian defense are the enzymes rhodanese and 
mercaptopyruvate sulfurtransferase.  These enzymes each detoxify cyanide by 
conversion to thiocyanate (SCN). Thiocyanate is much less toxic than cyanide 
and is eliminated principally by renal excretion. The clinically relevant differences 
between these cyanide detoxification enzymes are their substrates, reaction 
rates, and compartmentalization of the enzyme within the body.  
 Rhodanese (EC 2.8.1.1) was the first cyanide detoxification enzyme 
discovered (1933), and was purified in 1953. Rhodanese catalyzes the transfer of 
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sulfur from thiosulfate to cyanide, via an enzyme bound persulfide intermediate 
forming sulfite and thiocyanate. Rhodanese is compartmentalized mainly in the 
mitochondrial fractions of liver and kidneys, with little activity found elsewhere.  
 Mercaptopyruvate Sulfurtransferase (MST) (EC 2.8.1.2) was first 
described in 1953, and purified in 1955.76–78 The function of MST in cysteine 
catabolism can also detoxify cyanide by catalyzing the transferring a sulfur to 
cyanide, forming thiocyanate. The intermediate in this reaction, a persulfide at 
cysteine248 (cys248), is similar to that of rhodanese.79 The results of the MST 
reaction, in the presence of cyanide, are the formation of pyruvate and 
thiocyanate. However, MST and rhodanese diverge with respect to their 
compartmentalization. Unlike rhodanese, MST is found in both the mitochondrial 
and cytosolic fractions of many tissues including the blood, brain, liver, heart, and 
kidneys.  As a result, MST may have a greater potential than rhodanese for 
detoxifying cyanide.  
 Cyanide may also react non-enzymatically with other components of the 
cellular makeup. Cyanomethemoglobin can form upon addition of cyanide to 
methemoglobin in red blood cells, which decreases free cyanide concentrations 
at the expense of oxygen carrying capacity of the blood. Cyanide can also react 
with cysteine to form 2-aminothiazoline-4-carboxylic acid (ATCA), and 
endogenous keto-acids and sugars to form cyanohydrins.  
1.8 Current Approved Antidotes 
 Currently there are two FDA-approved cyanide antidotes available in the 
United States, nithiodote™ and hydroxocobalamin. Nithiodote™ consists of 
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intravenous infusions of sodium nitrate and sodium thiosulfate. The efficacies of 
the nitrates were originally thought to stem from nitrate’s ability to oxidize 
hemoglobin into methemoglobin, which bound cyanide. However, methemoglobin 
formation is too slow and inefficient to be effective. Peterson and Pearce 
demonstrated the primary mechanism of nitrate mediated antidotal efficacy was 
reduction of nitrite to of nitric oxide (NO), which competes with cyanide for the 
cytochrome C oxidase binding site.80 The other primary component of the 
cyanide antidote kit, sodium thiosulfate, is a substrate for the enzyme rhodanese. 
Rhodanese catalyzes the transfer of sulfur from thiosulfate to cyanide, forming 
thiocyanate (see above). When combined, these antidotes work together to 
scavenge, compete for the binding site, and detoxify free cyanide. The potential 
of this thiosulfate/nitrate combination was summarized in 1944 by Chen et al: 
“The two substances, intravenously injected…are capable of detoxifying 
approximately twenty lethal doses of sodium cyanide in dogs, and are 
effective even after respiration has stopped. As long as the heart is still 
beating, the chances of recovery by this method of treatment are very 
good.”81 
Hydroxocobalamin, also known as vitamin B12a and marketed as cyanokit™, is 
administered by intravenous infusion similarly to some components of the 
cyanide antidote kit. However, it differs from the cyanide antidote kit in its 
mechanism of action. Hydroxocobalamin contains a cobalt atom at its center, and 
similar to iron-containing enzymes, this cobalt directly binds and sequesters 
cyanide, decreasing free cyanide in the body (Figure 2). The Food and Drug 
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Administration (FDA) approved hydroxocobalamin in December 2006 under the 
FDA’s “Animal Rule”, which will be discussed later.  
 
Figure 2. Structure of hydroxocobalamin. The cobalt ion in hydroxocobalamin 
binds and sequesters cyanide. Image from Cyanokit™ package insert.82 
Permission not required for educational use.  
 
 There are other cyanide antidotes used outside of the United States. 4-
Dimethylaminophenol (DMAP) is an antidote used in Germany and Austria 
whose antidotal mechanism of action is attributed to production of 
methemoglobin from hemoglobin.37 Dicobalt EDTA is another chelating agent 
used in Europe. However, the utilities of both of these antidotes are limited by 
their side effects. Cobalt complexes (with noted exceptions being the corrins like 
hydroxocobalamin) are quite toxic, and DMAP administration can lead to 
hemolysis and multi organ failure in the absence of cyanide.37 For these reasons, 
the remainder of this document will focus on approved therapeutics in the US.   
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1.9 Issues with Current Antidotes 
 Both of the current FDA approved cyanide antidotes are not without their 
limitations. Nitrates (a component of nithiodote™) are dangerous to use in cases 
of smoke inhalation, as the resulting methemoglobin will decrease the oxygen 
carrying capacity of the blood. This reduced carrying capacity is further 
complicated by both: 1) exposure to carbon monoxide also present in many 
cases of smoke inhalation and 2) nitrate-mediated hypotension.83 For this 
reason, nitrates are contraindicated in cases of smoke inhalation, which is a 
major source of cyanide exposure. In instances where nithiodote™ is indicated, 
side effects require administration with thiosulfate to lower the required nitrite 
dose to limit this toxicity.83 
 Thiosulfate (a component of nithiodote™) has fewer side effects than 
nitrates, but is slower acting and requires an IV infusion. This slower onset is a 
function of its mechanism as a substrate for the enzyme rhodanase, which is 
concentrated mainly in the mitochondria of livers and kidneys. Sole 
administration of thiosulfate may leave critical, susceptible areas of cyanide 
toxicity such as the CNS or heart unprotected. However, emerging research has 
demonstrated sodium thiosulfate and nitrite administration (both IM) is more 
efficacious than previously thought.84 
 Hydroxocobalamin (cyanokit™) is a cyanide scavenger and is safe for use 
in smoke inhalation scenarios. Hydroxocobalamin’s low aqueous solubility 
requires a large volume intravenous infusion slowly administered (200 mL over 
15 minutes) in order to deliver a therapeutic dose. Additionally, its dark red 
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coloration persists in the body fluids for days, turning skin, blood, urine, sweat 
and tears a deep red. As a result, administration of hydroxocobalamin may 
interfere with diagnostic tests such as pulse oximetry (Figure 3).85 
 
 
 
Figure 3. Side effects of hydroxocobalamin administration. Red coloration of 
hydroxocobalamin persists in skin (above) and urine (below) for days. Images 
from Uhl and Borron.86,87 Permission not required for educational use.  
 
1.10 Properties of an Ideal Cyanide Antidote 
 The ideal antidote for cyanide poisoning needs to address the 
requirements for both the specific toxicant and likely exposure scenarios. For 
cyanide, antidotes need to be fast acting. Due to the rapid decline of individuals 
who are exposed to cyanide, the ideal antidote must start working rapidly. For 
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this reason, antidotes that take advantage of the rhodanese system are not ideal, 
because of the need for these compounds to distribute to the liver and kidney 
mitochondria, where most rhodanese is compartmentalized.  
 The antidote also must be safe. Currently there are no field-deployable 
methods for rapid identification of cyanide and medical countermeasures must be 
administered quickly; victims may not survive transportation to a hospital. 
Therefore, the antidote needs to be safe enough to administer even in instances 
where exposure to cyanide is only suspected.  
 Due to cyanide specific exposure scenarios such as smoke inhalation or 
mass casualty settings during an accidental or terrorist related release, the ideal 
antidote needs to account for these scenarios and retain efficacy and safety. For 
smoke inhalation scenarios, the oxygen carrying capacity of the blood should not 
be compromised. For this reason, antidotes which detoxify cyanide by forming 
methemoglobin are not ideal. Additionally, in mass casualty scenarios rapid and 
facile administration becomes of utmost importance. Currently approved cyanide 
antidotes all require some component of the antidote to be given intravenously 
(IV), which requires both trained medical personnel onsite as well as time to get 
the IV line started. Due to this rate-limiting step, in a mass casualty scenario 
there would be people who would succumb to the poison before medical 
countermeasure therapy could be administered. For this reason, the ideal 
cyanide antidote would not be given IV. Additionally, due to loss of 
consciousness and apnea associated with cyanide exposure, both oral and 
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inhalational routes of administration would not be optimal. Either intramuscular 
(IM) or intraosseous (IO) administration are preferred for cyanide antidotes.  
1.11 Next Generation Cyanide Antidotes 
 To address the issues with currently approved cyanide antidote 
countermeasures outlined above, next generation antidotes are in development 
with mass casualty scenarios in mind. Bhattacharya et al in India are developing 
α-ketoglutarate.58,88 The proposed mechanism of action for α-ketoglutarate is 
cyanohydrin formation at the α-keto acid moiety. Cyanohydrin formation is a 
reversible reaction, but any cyanohydrin present decreases the overall free 
cyanide available to inhibit cytochrome c oxidase. In a human dose fixation 
study, adverse events of α-ketoglutarate administration were vomiting and 
tachycardia, but did not halt development as an antidote.89  
 Cobinamide (Cbi) is an antidote under development by Boss and 
colleagues at the University of California, San Diego. Cobinamide is a 
biosynthetic precursor to the approved hydroxycobalamin and binds cyanide with 
greater affinity. It is also more soluble than hydroxocobalamin, as a result more 
amenable to other routes of administration in addition to IV.90 In both cell and 
animal models, Cbi has demonstrated efficacy at binding cyanide released by 
nitroprusside administration.91 It has also demonstrated efficacy in both non-
lethal and lethal cyanide doses in animal models by oral (PO) and intramuscular 
(IM) routes of administration.92–95 Cobinamide has not yet entered phase I clinical 
trials, but remains a promising new therapy.  
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 Rockwood, Petrikovics et al are developing an IM injectable formulation of 
dimethyl trisulfide (DMTS). DTMS is a sulfur donor, and is capable of converting 
cyanide into thiocyanate either in the presence or absence of rhodanase.96 This 
reduced reliance on an enzyme catalyst enables detoxification of cyanide in 
rhodanase deficient tissues. Moreover, the increased lipid solubility of DMTS 
when compared to thiosulfate allows DMTS to distribute more efficiently to the 
mitochondria, where rhodanase is compartmentalized.96 As with cobinamide, 
DMTS is in pre-clinical development.  
 Sulfanegen is an antidote undergoing evaluation by Nagasawa, Patterson, 
et al at the University of Minnesota and whose development, characterization, 
and clinical translation is the focus of this dissertation. Sulfanegen is a prodrug of 
3-mercaptopyruvate, the substrate for mercaptopyruvate sulfurtransferase. As 
discussed previously, this enzyme’s catalyzed reaction generates thiocyanate 
and pyruvate (Figure 4). Sulfanegen has demonstrated efficacy in murine, rabbit, 
and swine animal models of cyanide poisoning at both toxic sub-lethal and lethal 
cyanide doses.97–101 It has also shown efficacy when combined with other 
antidotes.102 The development of sulfanegen was recently summarized in the 
literature.99 As with cobinamide and DMTS, clinical trials for sulfanegen have not 
yet commenced.  
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Figure 4. The mechanism of Action of sulfanegen. Sulfanegen disassociates into 
two molecules of 3MP, which is the substrate for MST. MST catalyzes the 
conversion of cyanide to thiocyanate.  
 
1.12 Hurdles to Clinical Translation 
 Key data in the approval of any new drug is obtained via phase III human 
clinical efficacy studies. However, the ethical issues in evaluating cyanide 
efficacy in human populations present an additional challenge to the normal drug 
development process. The United States FDA recognizes this hurdle to clinical 
translation, and has published “Approval of New Drugs when Human Efficacy 
Studies are not Ethical or Feasible” (CFR 314 Subpart 1), more commonly 
referred to as the “animal rule”.103 These guidelines allow reliance on animal-only 
efficacy data for determining drug approval in cases when the following criteria 
are met:  
1) There is a reasonably well-understood pathophysiological mechanism 
of the toxicity of the substance and its prevention or substantial reduction 
by the product;  
2) The effect is demonstrated in more than one animal species expected 
to react with a response predictive for humans, unless the effect is 
demonstrated in a single animal species that represents a sufficiently well-
characterized animal model for predicting the response in humans;  
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3) The animal study endpoint is clearly related to the desired benefit in 
humans, generally the enhancement of survival or prevention of major 
morbidity; and  
4) The data or information on the kinetics and pharmacodynamics of the 
product or other relevant data or information, in animals and humans, 
allows selection of an effective dose in humans.103 
  
Criterion #1, the pathophysiological mechanism of cyanide toxicity, is well 
documented to be competitive inhibition of cytochrome C oxidase and resulting 
inhibition of oxidative phosphorylation. In addition, the previous animal model 
work completed by our lab shows clear benefit to sulfanegen administration in 
cases of cyanide exposure as well as endpoints clearly related to the desired 
outcome in humans (criterion #3). However, the two remaining criteria in the 
“animal rule” remain hurdles to clinical translation. Even though sulfanegen has 
shown efficacy in multiple animal models of cyanide poisoning, those models 
must have justification for why the results seen in those studies are expected to 
be predictive for humans. Additionally, the pharmacokinetics (PK) and 
pharmacodynamics (PD) must be understood well enough to determine an 
effective dose in humans. Addressing these remaining hurdles to clinical 
translation of sulfanegen is a major focus of this thesis.   
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CHAPTER II: 
IN-VIVO MERCAPTOPYRUVATE 
SULFURTRANSFERASE SPECIES COMPARISON IN 
HUMANS AND COMMON LABORATORY ANIMALS 
	  
	 27	
1. Introduction 
Upon exposure to cyanide, substrates for the endogenous detoxification 
enzymes MST or rhodanase are rapidly depleted. The resulting inability to 
detoxify cyanide results in inhibition of cytochrome C oxidase, leads to buildup of 
lactic acid and resulting metabolic acidosis.56 Time to death is dose dependent, 
occurring in minutes to hours if medical countermeasures in the form of either 
additional substrate (such as thiosulfate) or chelators (hydroxocobalamin) are not 
administered. Discussion of cyanide’s mechanism of toxicity and antidotal 
approaches are covered in Chapter 1.  
Sulfanegen is a prodrug of 3-mercaptopyruvate (3MP), the endogenous 
substrate for mercaptopyruvate sulfurtransferase (MST), and represents a novel 
mechanism of action for cyanide antidotes (Figure 5).101 However, ethical issues 
of testing the efficacy of chemical threat countermeasures in human clinical trials 
render phase 2 and 3 efficacy trials impossible. Therefore, additional care must 
be taken to justify the animal models for efficacy testing in order to determine a 
response predictive for humans, as laid out in the “animal rule” discussed in 
chapter 1. For MST based therapies, this would involve characterizing not only 
the MST activity, but also the localization of the enzyme activity for each species 
and comparison with human MST activity localization. 
Figure 5. Reaction scheme of sulfanegen (shown here as the sodium salt, 
sulfanegen sodium) and route of cyanide detoxification by MST. 
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We report here a species comparison study of MST activity to identify and 
select appropriate animal models to address point 2 (above). First, MST activity 
comparison in erythrocytes from commonly used laboratory species was carried 
out by my colleagues Dr. Daune Crankshaw and Ms. Jacquie Briggs. Based on 
these data, species with activities closest to that of human blood were more 
thoroughly examined in clinically relevant tissues. For this, liver and kidney 
samples were examined because MST is more abundantly expressed in these 
organs compared to others.5 These data should help selection and justification of 
animal models for sulfanegen use in humans. 
2. Methods 
All procedures involving collection of blood and tissue from animals were 
reviewed and approved by the University of Minnesota Institutional Animal Care 
and Use Committee (IACUC). The use of de-identified human organ samples 
from deceased individuals was ruled exempt by the University of Minnesota 
Investigational Review Board. 
2.1 Chemicals 
Tris-HCL, sodium cyanide, iron (III) nitrate nonahydrate, sucrose, 
ethylenediaminetetraacetic acid (EDTA), mammalian protease inhibitor cocktail, 
dithiothreitol (DTT), nitric acid, potassium chloride, and formaldehyde solution 
(38%) were purchased from Sigma Aldrich Co. (St. Louis, MO, USA). Sodium 
mercaptopyruvate was synthesized by Dr. Alexandre Monteil as described 
previously.101 
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2.2 Blood 
Fresh whole blood samples from healthy animals were collected in K2 
EDTA coated BD Vacutainer tubes, transported on ice, and centrifuged at 1,500 
x g for 10 minutes. The pellet containing red blood cells (RBC’s) was suspended 
in isotonic saline for manual hemocytometer counting and subsequently ruptured 
by freeze/thaw cycling prior to assay. All species had n=6 for both sexes, except 
for male Wistar rat (n=5), male human (n=8), male and female NZW rabbit (n=3), 
and male and female Yorkshire pig (n=4 and 5 respectively). 
2.3 Tissues 
Liver and kidneys from healthy Swiss-Webster mice (n=8), C57BL/6 mice 
(n=8), New Zealand White (NZW) rabbits (n=8), and Yorkshire pigs (n=3) were 
excised and snap-frozen at -80 °C until ready for homogenization. Human 
samples from smokers (n=6), nonsmokers (n=7), and those who had previously 
smoked but successfully quit (n=5) were obtained from the National Disease 
Research Interchange (NDRI). The homogenization buffer consisted of 200 mM 
sucrose, 1 mM EDTA, 2 mM DTT, 1.15% potassium chloride, Protease Inhibitor 
Cocktail, and 20 mM Tris-HCl pH 7.4. Samples were homogenized using a 
Fisher Scientific PowerGen 125 homogenizer, and centrifuged at 650 x g for 10 
minutes at 4 °C to remove cellular debris. The supernatant was collected and 
centrifuged at 17,000 x g for 10 minutes at 4 °C. The resulting supernatant was 
collected as the cytosolic fraction, and the pellet was suspended in 
homogenization buffer as the mitochondrial fraction. Samples were frozen at -80 
°C until ready to assay. 
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2.4 MST Enzyme Assay 
2.4.1 Blood 
MST activity in erythrocytes was measured according to the method of 
Valentine et al.104 Enzyme units were defined as µmoles of pyruvate generated 
per minute per 1010 RBC’s at 37 °C under assay conditions. 
2.4.2 Tissues 
Tissue cytosolic or mitochondrial fractions were diluted to a 1 mg / mL 
working solution in protease inhibitor as described below. The enzyme activity 
was then determined by the method of Taniguchi and Kimura.105 Specific activity 
was defined as µmoles thiocyanate formed per mg protein per minute.  
2.5 Protein Assay 
Protein concentrations were determined by Bradford assay using bovine 
serum albumin as a standard.106 
2.6 Statistical Analysis 
The data are expressed as the mean ± Standard Deviation (SD). 
Significance differences among the groups were determined by either unpaired t-
test with Welch’s correction or one-way ANOVA and followed by Dunnet’s test 
where appropriate. The software GraphPad Prism (Version 6.0, San Diego, CA, 
USA) was used for statistical analysis and the statistical significance was set at p 
< 0.05. 
3. Results 
MST activity in blood was detectable in all species tested except for swine. 
In this species the blood MST activity was below the limit of detection (Figure 6). 
There were no significant differences between sexes within a species except for 
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NZW rabbits (p=0.0050) when analyzed using an unpaired t-test with Welch’s 
correction. Human activity (113.3 +/- 7.5) was flanked by Wistar rat (430.0 +/- 
43.7) and Swiss-Webster mouse (140.1 +/- 16.8) being greater than human, and 
male NZW rabbit (72.3 +/- 6.0), macaque (40.8 +/- 3.6), and C57BL/6 mice (38.6 
+/- 18.1) being less than human. The data for all species were statistically 
significant from human when analyzed using a one-way ANOVA with Dunnett’s 
test. 
 
 
Figure 6. Species Comparison of MST activity in RBC. Enzyme units were 
defined as µmoles of pyruvate generated per minute per 1010 RBC’s at 37 °C 
under assay conditions. Data were collected by Briggs and Crankshaw, and are 
plotted as mean +/- SEM. 
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Using the results from the RBC assay, male NZW rabbit, Swiss-Webster 
mouse, and C57BL/6 mouse were chosen to further quantify MST activities in the 
liver and kidneys as they were the species with the closest activity to humans 
among those tested. Choosing two different mouse breeds also allows for 
investigation into how activity might vary between different breeds of the same 
species, and could illustrate the importance of breed selection within species. 
The Yorkshire pig was also chosen because although the RBC MST activity in 
that model was below the limit of detection for our method, sulfanegen was 
demonstrated effective in rescue of Yorkshire pigs from a lethal dose of cyanide. 
The results from the liver specific MST comparison are summarized in Figure 7. 
NZW rabbit had the highest activity in cytosolic samples (0.84 +/- 0.15) and were 
similar to human (0.69 +/- 0.12) and C57BL/6 mouse (0.48 +/- 0.12). In the 
mitochondrial liver samples, Swiss-Webster mouse had the highest activity (0.59 
+/- 0.06), and both NZW rabbit (0.33 +/- 0.09) and C57B/6 mouse (0.36 +/- 0.06) 
were similar to human (0.26 +/- 0.03). MST results from the kidney samples are 
summarized in Figure 8. Swiss-Webster mouse had the highest cytosolic activity 
(0.49 +/- 0.08) followed by NZW rabbit (0.40 +/- 0.10), humans (0.17 +/- 0.04), 
and C57BL/6 mouse (0.14 +/- 0.08). NZW rabbit had the closest kidney 
mitochondrial activity to humans (0.18 +/- 0.04 and 0.14 +/- 0.04 respectively). 
Interestingly, Yorkshire pig had very low MST activity once again in all samples 
tested. A one-way ANOVA with Dunnett’s test to compare samples to human 
activity showed no statistical difference from human in the liver mitochondrial 
fraction from NZW rabbits, and in the cytosolic samples from the Swiss-Webster 
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mouse. In the kidney, NZW rabbits were once again statistically non-significant 
for the mitochondrial, as was the C57BL/6 mouse for the cytosolic fraction. 
 
 
Figure 7. Mercaptopyruvate Sulfurtransferase liver production by subcellular 
fraction and species. Data are plotted as mean +/- SEM. Specific Activity was 
defined as µMoles SCN produced per mg protein per minute under assay 
conditions. * Signifies statistical significant differences from human cytosolic 
samples, while † signifies statistically significant differences from human 
mitochondrial samples. 
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Figure 8. Mercaptopyruvate Sulfurtransferase kidney production by subcellular 
fraction and species. Data are plotted as mean +/- SEM. Specific Activity was 
defined as µMoles SCN produced per mg protein per minute under assay 
conditions. * signifies statistically significant differences from human cytosolic 
samples, while † signifies statistically significant differences from human 
mitochondrial samples. 
 
 
Environmental factors may also influence MST activities. Cigarette smoke 
contains cyanide, and as previously reported, cyanide levels in blood peak 
immediately following smoking a cigarette (0.484 +/- 0.100 µmol/L compared to 
0.125 +/- 0.035 µmol/L basal levels).107 It is unknown what effects, if any, this 
chronic ingestion may have on the endogenous cyanide detoxification pathways. 
To examine the effects of chronic, low-level cyanide exposure on MST activity, 
human samples from smokers, non-smokers, and those who had previously 
smoked but quit were analyzed separately. In the liver, there was no change 
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seen in cytosolic MST activities between the three groups. However, in the 
mitochondria, the p value between the smokers and nonsmokers was statistically 
significant (p=0.0003) using a one-way ANOVA with Dunnett’s test. This is 
summarized in Figure 9. No significant differences were seen in the kidney 
samples between the three groups.   
 
Figure 9. Effect of smoking on liver MST activity. Data are plotted as mean +/- 
SEM. Specific activity is defined as µMoles SCN produced per mg protein per 
minute under assay conditions. † signifies statistically significant differences from 
non-smoking mitochondrial samples. 
 
4. Discussion 
Ideal animal models should closely reflect human system intended to 
model. For cyanide, this involves mirroring both the signs and symptoms (lactic 
acidosis, apnea, cardiac arrest and death) seen in human exposure. Wide 
diversity exists in the models used for cyanide research. There are differences in 
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cyanide administration mode, cyanide dose, and endpoint (i.e. lethality, recovery, 
neurological condition). These models are summarized in Table 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.  Common animal models of cyanide intoxication.  
 
The above species are reasonable models for cyanide exposure, since the 
symptoms following such exposure closely resemble those seen in humans, 
including lactic acidosis, apnea, and when appropriate death, with neurological 
deficit among survivors. However, animal models of antidotal treatment must 
take into account not only that the animal represents a reasonable model of 
human exposure to cyanide, but should also take into account the antidotal 
mechanism of the drug.  
In our judgment, in addition to being an appropriate model for cyanide 
intoxication, a reasonable animal model for evaluation of sulfanegen should also 
mimic the human metabolic pathways of the drug. Therefore the model’s 
expression of MST should be similar to the human expression, both in degree 
Group Species/Breed Administration Dose Reference 
Canine Beagle IV Lethal 108 
 Beagle IV Lethal 109 
 Beagle IV Non-Lethal 109 
Feline Domestic Cat IV Non-Lethal 110 
Murine C57BL/6 IP Lethal 102 
 C57BL/6 Inhalation Lethal 102 
 NSA IP Non-Lethal 111 
 Swiss Webster IP Non-Lethal 112 
 Swiss Webster IP Non-Lethal 113 
Rabbit NZW IV Non-Lethal 92 
 NZW IV Lethal 114 
 NZW Oral Lethal 93 
Swine Yorkshire IV Lethal  115 
 Yorkshire IV  Lethal 116 
Aquatic Zebrafish Environmental Lethal 117 
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and distribution of MST activities. An animal model that fits the above should 
then reasonably allow prediction of human cyanide antidotal efficacy and 
toxicology. However, the Yorkshire pig (swine) model appears to be an 
exception, despite our reproducible observation that sulfanegen treatment fully 
protected Yorkshire pigs from lethal doses of cyanide swine have very low MST 
activity.116 Possible explanations for this observation could be that a low level of 
MST activity is sufficient, or that secondary mechanisms could offset the 
decreased thiocyanate production.  
5. Conclusions 
A careful consideration of both overall MST activity and intracellular 
compartmentalization of this activity is imperative in the selection of appropriate 
animal models for consideration under the animal rule. However, because no 
animal model tested was a perfect match to humans, demonstrated antidotal 
efficacy in animals with MST activity flanking both above and below that of 
humans lends credibility to predicted efficacy in humans. We report the 
comparability of NZW rabbits and C57BL/6 mice to humans, since MST activities 
in these species were most similar to humans in physiologically relevant tissues. 
The Swiss-Webster mouse comparability to human blood activity should also 
warrant consideration when choosing an animal model, as there may be an 
advantage to using both murine breeds as models. Although sulfanegen rescued 
Yorkshire pigs from a lethal dose of cyanide, the low levels of MST activities we 
observed in blood as well as in the liver and kidneys exclude it from further 
consideration. Nevertheless, this effect suggests efficacy could be expected even 
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in MST deficient humans. In addition, the metabolic fate of thiocyanate, the 
product of sulfanegen’s action on cyanide, should also be seriously considered. 
Thiocyanate is excreted in urine, thus animal models should eliminate 
thiocyanate via renal excretion with half-lives similar to humans. Although we 
only addressed MST location and activity here, these data should be 
consolidated with the thiocyanate elimination data to more accurately identify the 
justified species for MST efficacy. Comparative thiocyanate kinetics will be 
addressed in due course.  
This account was published in Toxicology Letters:  
Moeller BM, Crankshaw DL, Briggs J, Nagasawa H, Patterson SE. In-Vitro 
Mercaptopyruvate Sulfurtransferase Species Comparison in Humans and 
Common Laboratory Animals. Toxicol Lett. 2017. 
doi:10.1016/j.toxlet.2017.04.005.118 
 
The author of this dissertation’s contribution to the above paper was the liver and 
kidney follow-up studies to blood MST results. This involved the procurement, 
homogenization, differential centrifugation, data collection and analysis for tissue 
specific species comparison, as well as intellectual input on selection of 
appropriate species for the liver and kidney studies.  
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CHAPTER III:  
HPLC METHOD DEVELOPMENT FOR 
PHARMACOKINETICS OF SULFANEGEN 	  
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1. Introduction 
Upon absorption, a drug must be distributed to the target in order to 
achieve the therapeutic effect; absorption into the blood must then be followed by 
exit of the drug from the cardiovascular system (except for cardiovascular drugs 
e.g. antihypertensives), entry to targeted system and this process involves 
crossing multiple biological or cellular membranes. This complex interaction 
between the body and drug is mediated by the physiochemical properties of the 
drug: size, charge, and hydrophobic properties determine efficiency in crossing 
biological membranes and distribution to the target.119 Additionally, the desired 
effect can only be achieved as long as an effective concentration is maintained at 
the target. For most cases, concentration of the drug is decreased by 
metabolization into an inactive form and/or excretion in urine.119 The study of the 
rate of drug absorption, distribution, metabolism, and excretion is 
pharmacokinetics (PK). Characterizing PK is an integral part of the drug 
development process,120  should help explain sulfanegen’s rapid reversal of 
cyanide toxicity, and will be required to satisfy the animal rule. 
The second condition of the “Animal Rule” for drug approval is that the 
pharmacokinetics are understood well enough to determine an effective dose.103 
The Logue and Patterson labs recently published pharmacokinetic data for 
sulfanegen in cyanide naïve rabbits (Figure 10).122 Plasma concentrations of 
3MP were 1775 µM at Cmax, with T1/2 of nearly 2 hours. Furthermore, efficient 
catalytic turnover requires a sulfur acceptor such as cyanide. In the absence of 
such an acceptor, enzyme bound persulfide accumulates – rendering the 
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enzyme unable to catalyze the desulfuration of 3MP. This inhibits further 
metabolism of 3MP, establishing the need for characterizing PK both with and 
without concurrent cyanide administration.  
Figure 10. Pharmacokinetics of Sulfanegen in rabbits. Plasma concentrations of 
3MP in the absence of cyanide were 1775 µM at Cmax, with T1/2 of nearly 2 hours. 
Image from reference 122. Permission not needed for educational use. 
 
Finally, an additional need for clinical translation of sulfanegen is a 
validated stability-indicating method that can separate sulfanegen from precursor 
molecules used in synthesis (bromopyruvic acid), as well as decomposition 
products such as β-hydroxypyruvic acid). This is necessary for quality assurance 
of the drug as well as determination of shelf-life and acceptable storage 
conditions. Here, we describe a simple UV-VIS HPLC method for sulfanegen 
detection. The method is suitable for sulfanegen purity and stability 
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determination, and is amenable to biological specimens such as human plasma 
with minimal modification.  
2. Methods 
2.1 Reagents 
All solvents were HPLC grade unless stated otherwise. Sulfanegen 
Sodium was synthesized in our lab by Dr. A Monteil and Dr M Baran as 
described previously.97 N-ethylmaleimide (NEM), monobromobimane (MBB), β-
hydroxypyruvic acid, bromopyruvic acid, and Sulfuric Acid were purchased from 
Sigma-Aldrich (Saint Louis, MO, USA), Acetone and acetonitrile (ACN) was 
purchased from Fischer Scientific (Waltham, MA, USA). Maleic acid was 
purchased from Sigma-Aldrich (Saint Louis, MO, USA) and used as an internal 
standard. A 2.5 mM standard solution of Sulfanegen sodium (resulting in 5 mM 3-
MP) was freshly prepared and serially diluted in Millipore filtered water or plasma. 
Commercial reagents were used without further purification. 
2.2 Biological fluids 
Pooled plasma from n=12 humans was purchased from Memorial Blood 
Centers (St. Paul, MN) and stored at -80 °C until ready to use.  
2.3 Preparation of Samples 
2.3.1 Biological Samples 
Sample preparation followed the method of Stutelberg et al, with the 
following modifications: NEM derivitization rather than MBB, maleic acid as an 
internal standard, and reconstitution in deionized water containing NEM.114 Blank 
or 3MP spiked human plasma (100 µL) and 50 µM maleic acid (internal standard) 
were added to a 1.5 µL microcentrifuge tube. Plasma proteins were precipitated 
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by addition of 300 µL acetone followed by centrifugation at 16,500 x g for 30 
minutes at 4 °C.  The supernatant was dried under N2 and reconstituted in 100 
µL NEM followed by incubation at room temperature for 15 minutes. NEM 
derivitizes thiols, which prevents reformation of the reversible 3-MP dimer 
(Figure 11). Non-derivitized 3MP produces chromatograms unfit for 
quantification because the equilibrium between the sulfanagen dimer and 3MP 
monomer results in unacceptably broad peaks. Prepared samples were stored at 
4 °C until ready for HPLC analysis.  
2.4 Biological HPLC Analysis of 3MP-NEM 
An Agilent 1200 series HPLC coupled to an Agilent G1315B diode array 
detector (DAD) was used for UV/Vis HPLC analysis. Separation was performed 
on a Phenomenex ROA Organic Acid H+ (8%) column (300 x 7.8 mm, 8 µM) with 
an injection volume of 10 µL. The mobile phase consisted of isocratic 0.0075 M 
H2SO4 with 15% acetonitrile at a flow rate of 0.5 mL / min. Column temperature 
was set to 80 °C, with a total run time of 30 minutes. All analytes were detected 
by absorption at 212 nm. 
2.5 Purity and Stability HPLC Analysis of 3MP-MBB 
An Agilent 1200 series HPLC coupled to an Agilent G1315B diode array 
detector (DAD) was used for UV/Vis HPLC analysis. Separation was performed 
on a Phenomenex ROA Organic Acid H+ (8%) column (300 x 7.8 mm) with an 
injection volume of 10 µL. The mobile phase consisted of isocratic 0.01 M H2SO4 
at a flow rate of 0.5 mL / min. Column temperature was 70 °C, with a total run 
time of 20 minutes. Synthesized sulfanegen was derivitized with 
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monobromobimane (MBB) by heating at 70 °C for 15 minutes in deionized water. 
All analytes were detected by absorption at 212 nm. 
2.6 Calibration, Quantification, and Limit of Detection 
For validation of the method, the FDA bioanalytical method validation 
guidelines were followed.123 The initial calibration curve was prepared with 0.5 
µM-10 mM 3MP-NEM standards in plasma (0.5, 1, 2, 3, 4, 5, 7.5, 10, 25, 50, 100, 
250, 500, 1000, 2000, 3000, 4000, 5000 µM) to determine linear range. 3MP-
NEM calibration curves were created in both plasma and water to determine 
effects of the biological matrix. Quality Controls (n=5) were prepared at 3 
concentrations that were not on the calibration curve: 250 µM (high QC), 75 µM 
(mid QC), and 25 µM (low QC). Both internal standard and QC samples were 
prepared fresh daily for intra and inter-assay accuracy and precision studies. 
Precision was determined as %RSD. 
Limit of detection was defined as the lowest concentration that regularly 
gave a signal to noise ratio of at least 3, with baseline noise directly adjacent to 
the 3MP-NEM peak. 3MP is naturally present in the blood of humans, but is 
below the limit of detection for this assay.  
 
Figure 11. Derivitization of 3MP prevents reformation of the sulfanegen dimer. 
Without derivitization, reversible dimer formation creates chromatographic peaks 
unfit for detection. The NEM derivitization reaction is shown here. 
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2.7 Recovery 
Low (25 µM), mid (50 µM), and high (250 µM) concentration 3MP quality 
controls (n=3) were added to plasma prior to sample preparation. Percent 
recovery of 3MP was determined by dividing the method determined plasma 
concentration by the known concentration added.  
3. Results and Discussion 
3.1 HPLC analysis of 3MP in human plasma  
Irreversible derivitization of the 3MP monomer is required to trap the 3MP 
monomer therefore preventing reformation of the sulfanegen dimer. Commercial 
reagents are readily available for thiol derivitization, and are reviewed 
elsewhere.124 Multiple thiol-specific derivitization compounds were tested, and 
NEM was selected for biological samples because it gave the best separation 
from endogenous peaks in the blank human plasma controls. Figure 12 shows 
representative chromatograms of IS alone, IS spiked plasma, and 3MP-NEM + IS 
spiked plasma. The 3MP-NEM derivative eluted at 12.9 minutes, maleic acid IS 
eluted at 11.0 minutes, and any excess unreacted NEM eluted at 27 minutes. 
The method has good selectivity and no endogenous plasma peaks co-elute with 
peaks of interest.  
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Figure 12. Representative chromatograms. Top: Maleic acid (IS) alone. Middle: 
IS spiked human plasma. Bottom: 3MP-NEM IS spiked human plasma. Maleic 
acid elutes at 10.0 minutes, while 3MP-NEM elutes at 13.2 minutes.  
 
3.1.1 Linear range, limit of detection, and sensitivity 
Calibration curves of 3MP were prepared in the range of 0 to 5,000 µM in 
human plasma. The signal ratio (peak area / IS peak area) was used as the 
corrected signal. The linear range for this method was determined to be 5 µM to 
1,000 µM with an R2 of 0.99997. The limit of detection for the method was 5 µM 
3MP-NEM. Matrix effects between calibration curves compared in plasma and 
water were minimal. 
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3.1.2 Accuracy and precision 
Accuracy and precision were determined by analysis of low, mid, and high 
quality controls (n=5) on three consecutive days (Table 3). The intra-assay 
accuracy (<5%) and precision (<3) as well as the inter-assay accuracy (<5%) and 
precision (<6) were sufficient for detecting small molecules in biological matrices.  
Concentration 
(µM) 
Intra-assay 
accuracy 
Intra-assay 
precision 
Inter-assay 
accuracy 
Inter-assay 
precision 
25 -0.79% 0.12 +2.9% 3.96 
75 +4.3% 0.36 +0.26% 5.81 
250 +4.9% 2.8 +4.7% 3.03 
Table 3. Accuracy (%) and precision (RSD) of method for detecting 3MP in 
spiked human plasma. 
 
3.1.3 Recovery 
 Recovery from biological samples was poor (<40%), but consistent. 3MP 
is inherently unstable at biological pH, and although the same sample 
preparation method was used as Stutelberg et al in rabbits, recovery from human 
plasma samples were lower than in that method (75%). Incomplete recovery can 
be explained by MST conversion in the plasma, and represents an area for 
improvement. Human plasma MST activity from chapter 1 was 114 +/- 5.0, while 
NZW rabbit MST activity for males was 72.3 +/- 6.0 and for females was 32.0 +/- 
1.5. The sex of the individual rabbits in the Logue study was not provided with 
the samples; this difference may explain the recovery differences seen in the 
present study if samples from both male and female rabbits were included. 
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3.2 HPLC analysis of 3MP Purity and Stability 
 For the stability and purity indicating method, the derivitization reagent of 
choice was MBB. MBB yielded the best limit of detection while shifting the elution 
time of 3MP far from either β-hydroxypyruvic acid, bromopyruvic acid (Figure 
13). 3MP-MBB elutes at 8.1 minutes, while β-hydroxypyruvic acid and 
bromopyruvic acid elute at 11.1 and 12.9 minutes respectively. The limit of 
detection of 3MP-MBB was 50 nm, while the limits of β-hydroxypyruvic acid and 
bromopyruvic acid were 2.4 and 50 µM respectively. With sufficient distance 
between elution time of 3MP derivitized with MBB and either β-hydroxypyruvic 
acid or bromopyruvic acid, the relatively low limits of detection of bromopyruvic 
acid can be overcome by injection of larger sample volume to the column. 
 
 Figure 13. Representative chromatograms for stability and purity indicating 
method. Chromatogram is 100 µM 3MP-MBB (S-MBB), 500 µM β-hydroxypyruvic 
acid (HPA) and bromopyruvic acid (BrPA).  
 
4. Conclusions 
An HPLC method was developed for the quantification of 3MP with 
applications to both biological quantification and quality control. This simple 
method employs UV detection and is readily amenable to many laboratories 
without the need for more expensive detection equipment. The low temperature 
of the NEM derivitization reaction is also ideal for the quantification of 3MP, due 
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to 3MP’s low aqueous stability at high temperatures. The linear range is also 
appropriate for biological studies, and plasma concentrations determined from 
previous studies would require minimal dilutions for analysis. There is room for 
improvement in regards to recovery of the biological method. Because 3MP 
increases in stability with decreasing pH beginning at pH 5, acidification before 
protein removal should yield better results. Additionally, the limit of detection of 
the quality control method could be improved with further derivitization of the 
carboxylic acid. This was not pursued further as the column chosen is specific to 
carboxylic acids, and derivitization would likely require selection of a different 
column. Moreover, the goal of a reasonable method for quality assurance was 
achieved.  
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CHAPTER IV: 
SECONDARY MECHANISM ELUCIDATION 
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1. Introduction 
The primary mechanism of action of sulfanegen in cyanide detoxification is 
MST catalyzed conversion of cyanide to thiocyanate, with 3MP/sulfanegen as the 
sulfur donor. This mechanism is supported by the observed conversion of 
cyanide to thiocyanate described Chapter 1, as well as previous studies detailing 
the selectivity of substrates between MST and rhodanase.118,125,126 Previously 
published works from our lab have shown sulfanegen is more efficacious when 
administered 5 minutes before cyanide in the righting reflex assay than either of 
the currently approved cyanide antidotes: either a combination of thiosulfate and 
sodium nitrite (nithiodote™) or hydroxycobalamin (cyanokit™).101,113 Additionally, 
when administered 5 minutes after a toxic yet sub-lethal dose of cyanide, 
sulfanegen was still highly effective, while other cyanide antidotes showed only 
minimal protection when compared to controls (Figure 14).101 At twenty minutes 
post cyanide, sulfanegen reduces recovery time whereas nithiodote™ and 
cyanokit™ are ineffective at reducing recovery time.101 
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Figure 14. Effects of cyanide antidotes on righting reflex time. Antidotes 
administered 5 minutes after sub-lethal cyanide dose. Adapted from 101 
T/N=Thiosulfate/Nitrite combination H=Hydroxycobalamin			
 
Therefore, sulfanegen appears to be more efficacious and may have a 
longer treatment window than currently available antidotes. Additionally, since 
cyanokit™, a chelator, was ineffective when administered 20 minutes after 
cyanide, it is likely there is no longer free circulating cyanide at that time. This 
raises the question: why is sulfanegen effective at time points where other 
antidotes have little or no effect. The stark difference in righting reflex time could 
be attributed to the ubiquitous distribution of MST, which provides a combination 
of benefits: 1) being distributed in both the cytosolic and mitochondrial fractions 
2) being expressed in the most sensitive tissues to cyanide exposure such as the 
CNS.127 However, the possibility of secondary mechanisms of action contributing 
to overall efficacy has not been ruled out. Elucidating these possible secondary 
mechanisms and establishing their relative contributions are the focus of this 
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chapter, and could open the door to designing antidotes that are even more 
efficacious in the future. 
It has previously been demonstrated that in addition to transferring sulfur 
to cyanide, MST also produces hydrogen sulfide (H2S).128 Concentrated H2S is a 
potent neurotoxin, but more recent studies have shown lower levels of H2S act as 
an endogenous neuromodulator in the brain.129,130 H2S induces calcium 
release,130 can protect neurons from oxidative stress,131–134 is a smooth muscle 
relaxant,135 vasodilator,136 and has antioxidant roles in reducing inflammation.137–
140 Of primary interest to us is the ability of H2S to provide neuronal protection 
from oxidative stress, which has been postulated to be a downstream effect of 
cyanide toxicity.59,141,142 Therefore, if significant amounts of H2S are also 
produced by MST following sulfanegen administration, quenching oxidative 
stress via MST may be a previously unaccounted for mechanism of action that 
could help explain the differences in efficacy between sulfanegen and other 
enzyme based antidotes. 
In addition to H2S production, sulfanegen may have other means of 
quenching cyanide-induced oxidative stress. Thiols are reducing agents and are 
therefore known to have antioxidant properties of their own,143 with glutathione 
being the most common and widely studied.144–146 During cyanide toxicity, there 
is a marked decrease in glutathione levels due to the increase in ROS 
generation.58 Therefore, it is possible sulfanegen is able to directly decrease 
ROS since it is a prodrug of a low molecular weight thiol. 
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Finally, some α-keto acids such as α-ketoglutarate have shown efficacy in 
protection from cyanide exposure, even though they lack the thiol group required 
for reduction of ROS or utilization by MST.58,88,147 Such ketones (and aldehydes) 
react with cyanide, forming cyanohydrins. 3MP is an α-keto acid, and therefore 
may form a cyanohydrin. 
We hypothesized that sulfanegen efficacy is partly due to secondary 
mechanisms such as cyanohydrin formation or quenching cyanide-induced 
reactive oxygen species (ROS) - either indirectly through MST generation of H2S 
or directly as a reducing thiol. These mechanisms are summarized in Figure 15. 
 
Figure 15. Potential mechanisms of sulfanegen. Sulfanegen disassociates into 
two molecules of 3MP, which are then able to: (1) act as a substrate for the 
enzymatic conversion of cyanide to thiocyanate by MST, (2) indirectly quench 
cyanide induced ROS via MST production of H2S, (3) directly quench cyanide 
induced ROS by acting as a reducing thiol, (4) directly detoxify cyanide via 
reversible cyanohydrin formation. 
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2. Methods 
2.1 Cell Culture 
To test the hypothesis that sulfanegen quenches cyanide-induced ROS 
through generation of H2S, an immortalized rat mesencephalic cell line, 1RB3N27 
(N27), was used. This dopaminergic cell line was chosen because it has been 
used extensively in mechanistic studies of cyanide and other neurotoxin 
poisoning,148–151 as well as being the cell type most likely involved in the 
pathology of Parkinsonian-like symptoms associated with sub-lethal cyanide 
exposure.152–154 Cells were plated in Roswell Park Memorial Institute (RPMI) 
media containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. 
Cells were grown to 80% confluency as previously described by Adams et al.155  
2.2 ROS Quenching: DDPH Assay 
To determine sulfanegen’s ability to act as a reducing thiol, the 2,2-
diphenyl-1-picrylhydrazyl (DPPH) assay was used to test ROS quenching in-
vitro. DPPH exists in solution as a stable free radical with a deep purple 
coloration (515 nm). This color becomes pale yellow upon quenching of the 
stable radical by antioxidants, and is therefore a useful indicator of antioxidant 
efficacy and kinetics by determining changes in absorbance at 515 nm over 
time.156–158 The DPPH assay was performed as described by Xie et all.158 DPPH 
was freshly dissolved in 50:50 water/methanol to prepare a 0.0913 mM DPPH 
solution and protected from light with aluminum foil. 3MP, GSH, NAC, or 
Ascorbic Acid (10 µL of 0.5-500 mM) were added to 1mL of 0.0913 mM DPPH 
containing cuvette (0.5-500 µM final concentration antioxidant) and the 
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absorbance at 515 nm was recorded every second for 10 minutes using a 
SpectroMax M5e spectrophotometer.  
2.3 ROS Quenching: DCFH-DA Assay 
To determine the in-vivo potential of sulfanegen to quench cyanide 
induced ROS, 2,7-dichlorofluorescin diacetate (DCFH-DA), which is commonly 
used as an ROS probe, was employed.58 DCFH-DA is able to freely pass through 
the cellular membrane, where it is deacetylated by cellular esterases and trapped 
within the cell. ROS then oxidizes the non-florescent compound into a florescent 
product detected at 495ex / 529em.  N27 cells were plated 15,000 cells/well in a 96 
well plate and incubated overnight. The next day, cells were washed in PBS, and 
pre-incubated with 100 µM DCFH-DA for 30 minutes. After the pre-incubation, 
cells were washed with PBS and 0-400 µM 3MP, GSH, or NAC were added 
along with 500 µM H2O2. Florescence was measured with a microplate reader 
every 5 minutes for 2 hours at 495ex /529em using a SpectroMax M5e 
spectrophotometer. 
2.4 Determination of GSH Concentration 
To determine the effects of sulfanegen in the presence of ROS on cellular 
redox state, GSH concentrations were determined using the Abcam GSH Ratio 
Detection Assay Kit II (ab205811). Confluent N27 cells were plated in 6 well 
plates at 1 million cells/well and incubated overnight. The following day, 0-200 
µM 3MP were added along with 500 µM H2O2 and incubated for 4 hours at 37 °C. 
After 4 hours, cells were washed in ice cold PBS and lysed with mammalian lysis 
buffer (Abcam) and protease inhibitor cocktail (Sigma). Following lysis, cells were 
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centrifuged at 1,500 x g for 5 minutes to pellet cellular debris. The supernatant 
was assayed according to kit protocol.159 
2.5 Determination of H2S Generation  
To determine the effects of sulfanegen administration on MST H2S 
generation, the H2S sensitive probe 4-chloro-7-nitrobenzofurazan (NBD-Cl) was 
utilized. Human liver cytosolic fractions were prepared according to Moeller et 
al.118 For the H2S assay, all solutions were sparged with nitrogen to remove 
dissolved oxygen. To determine H2S production following sulfanegen 
administration, 50 µM NBD-CL was added with 50 µL lysate and 0-500 µM 3MP 
in 50 mM PIPES, 0.1% ascorbic acid, and 100 mM KCL either in the presence or 
absence of sodium cyanide or ROS and incubated at 37 °C for 15 minutes. NBD-
Cl reacts with H2S and the resulting fluorescent product was monitored at 534 
nm using a SpectroMax M5e spectrophotometer. 
2.6 Cyanohydrin formation – analytical chemistry approaches 
A 3MP solution (aqueous, 50 mM) was treated with 50 mM aqueous NEM 
by incubating 15 minutes at room temperature to prevent reformation of the 3MP 
dimer. This 25 mM stock solution of 3MP-NEM was diluted (water) to 1 mM and 
incubated with an equimolar concentration sodium cyanide in water at room 
temperature for 30 minutes. Following incubation, the reaction mixture was 
analyzed using mass spectrometry (MS) in MMI Mixed Negative mode.   
2.7 Cyanohydrin Formation – Cytochrome C Oxidase 
To determine if cyanohydrin formation plays a biological role in preventing 
cyanide inhibition of cytochrome c oxidase, the cytochrome C oxidase assay kit 
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(CYTOCOX1, Sigma Aldrich) was used. NaCN (0-40 µM in water) was added to 
the aqueous reaction mixture containing cytochrome and cytochrome c oxidase 
to quantify inhibition. This was repeated with cyanide being first incubated at 
room temperature with an equimolar concentration of 3MP-NEM to complex 
cyanide. Oxidation of cytochrome c was monitored at 550 nm every second for 1 
minute using a SpectroMax M5e spectrophotometer. 
3. Results 
3.1 DPPH Assay 
The DPPH assay was performed on NAC, GSH, 3MP, and ascorbic acid 
in 50:50 methanol/water. There were no discernable differences in the 
absorbance for any antioxidant tested at 0.5 µM or 1 µM. At higher 
concentrations, ascorbic acid acted the fastest, reaching equilibrium before 
measurements were performed. Every ascorbic acid concentration tested above 
50 µM fully quenched the DPPH radical (Figure 16). 3MP demonstrated the 2nd 
fastest reaction kinetics; with both 500 µM and 250 µM concentrations reaching 
complete quenching of DPPH by the end of the reaction time (Figure 17). Both 
NAC and GSH lagged behind 3MP, with even the highest concentrations test not 
fully quenching the DPPH radical during the time allotted (600 s) (Figures 18 & 
19). These results are most readily apparent when overlaid (Figure 20). 
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Figure 16. Dose response curve of ascorbic acid quenching the DPPH radical. 
The reaction was nearly instantaneous and all concentrations tested above 25 
µM fully quenched the radical.  
 
	
Figure 17. Dose response curve of 3MP quenching the DPPH radical.	
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Figure 18. Dose response curve of NAC quenching the DPPH radical. 	
	
Figure 19. Dose response curve of GSH quenching the DPPH radical. 	
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Figure 20. Antioxidant quenching of DPPH radical where concentration of 
antioxidant are roughly equivalent to DPPH radical (91.3 µM DPPH 100 µM 
antioxidant).  3MP = 3-mercaptopyruvate, GSH = glutathione, NAC = N-
acetylcysteine, AA = ascorbic acid. 	
3.2 DCFH-DA Assay 
Biological relevance of the DPPH radical results was tested in vivo using 
the DCFH-DA assay to determine intracellular ROS generation. The same 
general trend of antioxidant activity was seen in the DCFH-DA assay as the 
DPPH radical scavenging assay. Out of the three compounds tested, 3MP 
demonstrated the greatest antioxidant activity, followed by NAC and GSH (~80%, 
60%, and 40% reduction in relative florescence at 100 µM respectively) as shown 
in Figure 21. This is consistent with 3MP’s antioxidant activity in vitro being 
enhanced by MST’s ability to produce H2S.  
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Figure 21. Dose response of ROS quenching by NAC, 3MP and GSH in N27 
cells using the DCFH-DA assay. 
3.4 GSH Concentration 
Sulfanegen’s antioxidant ability resulting in quenching ROS was evaluated 
by measuring GSH concentration in N27 cells. As sulfanegen concentration 
increased from 0 or 50 to 200 µM intracellular GSH increased (Figure 22). While 
200 µM 3MP was unable to fully recover GSH levels to those in the negative 
control (no H2O2 added), higher concentrations of 3MP may yield full recovery. 
Overall, higher concentrations of 3MP correlated to higher concentrations of 
GSH, demonstrating lower overall oxidative damage to the cells as 3MP 
quenched ROS. This is consistent with antioxidant properties of 3MP contributing 
to 3MP’s mechanism of cyanide antagonism. 
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 Figure 22. The effect of 3MP administration on intracellular GSH concentration. 
Negative control is lacking ROS and 3MP.  
3.3 H2S Generation 
 Generation of H2S was monitored using NBD-Cl and measuring UV 
absorbance at 534 nm. H2S formation increased in the presence of MST, and in 
the presence of peroxide absorbance nearly doubled (Figure 23). Therefore, 
when challenged by ROS, available 3MP likely quenches ROS, preventing or 
limiting cellular damage. NBD-CL reacts slowly with 3MP alone, and in the 
absence of MST the decrease in absorbance seen in the 3MP + H2O2 assay 
provides indirect evidence of 3MP’s antioxidant effect, as the resulting disulfide 
does not react with NBD-CL. 
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Figure 23. H2S formation in the presence or absence of MST. 	
3.4 Cyanohydrin Formation 
Under the conditions outlined above, cyanohydrin formation was detected 
via mass spec, albeit in smaller than expected ratios. The peak with a 
mass/charge ratio (m/z) of 244 corresponds to 3MP-NEM, while the peak with 
(m/z) 271 corresponds to the resulting 3MP-NEM cyanohydrin. A representative 
mass spectrum is given in Figure 24. Peaks corresponding to double the 
expected mass charge ratios are present, which is a common artifact of that 
spectrometer.  
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Figure 24. Mass Spectroscopy Results of Cyanohydrin formation. M/Z 244 is 
3MP-NEM, while 271 peak corresponds to resulting cyanohydrin. 	
3.5 Cytochrome C Oxidase Assay 
Under the conditions described above, 40 µM concentration of sodium 
cyanide fully inhibited cytochrome c oxidase, matching the negative control 
devoid of cytochrome c oxidase. Half of that dose (20 µM) of sodium cyanide 
produced a 50% inhibition when compared to the positive control containing no 
cyanide. When 20 µM cyanide was incubated with 20 µM 3MP for half an hour 
before the assay, cytochrome C oxidase activity closely resembled the activity of 
20 µM NaCN alone (Figure 25). This is inconsistent with cyanohydration 
formation contributing to the mechanism of cyanide antagonism. 
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Figure 25. Cytochrome C oxidase activity in the presence or absence of 3MP & 
cyanide. Blank samples contained no cytochrome C oxidase, while the positive 
control had cytochrome C oxidase without cyanide present. 	
4. Discussion 
The potential mechanisms of sulfanegen administration are summarized 
below in Table 4. Enzymatic conversion of cyanide to thiocyanate is the primary 
mechanism of action of sulfanegen, and therefore responsible for most of the 
efficacy. However, the demonstrated efficacy in pigs, even in the absence of high 
MST activities, are evidence of biologically relevant secondary mechanisms. 
Sulfanegen’s ability to directly reduce ROS was first examined in the DPPH 
radical assay, where it was more effective at quenching ROS than NAC or GSH. 
These results were confirmed in cell culture, where it was more effective than 
NAC or GSH at quenching ROS in the N27 cell line. Analysis of reduced 
glutathione after administration of sulfanegen and ROS showed less oxidative 
stress on the cells.  
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The ability of sulfanegen to non-enzymatically detoxify cyanide via the 
reversible cyanohydrin reaction was examined using both analytical chemical 
and biochemical techniques. Cyanohydrin formation was detected at low levels in 
the mass spectrum, but this is not a direct demonstration of biological relevance. 
A better approach would be to demonstrate sulfanegen’s ability, or lack thereof, 
to restore Cytochrome C oxidase activity after cyanide administration in the 
absence of MST. In the assay, 20 µM of 3MP incubated with cyanide were 
statistically the same as 20 µM cyanide alone, demonstrating that cyanohydrin 
formation, even if formed in detectable amounts by mass spectrometry, had no 
measurable effect on cytochrome C oxidase activity. This is likely due to both the 
small amounts of free cyanide being removed from the system via cyanohydrin 
formation, as well as the formation of cyanohydrin being reversible. It is also 
possible that cyanohydrin formation observed by MS was an artifact of the 
conditions in the mass spectrometer i.e. the cyanohydrin formed in the source 
chamber of the spectrometer but not necessarily in solution. Thus, it appears 
cyanohydrin formation does not contribute to sulfanegen’s antagonism of cyanide 
toxicity. 
Quenching of cyanide induced ROS via enzymatic conversion of 3MP to 
H2S, was the final mechanism examined. In the presence of MST, 3MP produced 
higher levels of H2S than 3MP incubation with the probe alone. At this time, the 
biological significance of this reaction is unknown, but it is expected to help 
ameliorate cyanide induced ROS. These mechanisms are likely to contribute to 
the overall efficacy of sulfanegen. 
	 68	
	
Potential 
Mechanism Order Mechanism 
Ex-vivo 
Detection? 
Biologically 
Relevant? 
Detoxification of 
Cyanide 
Primary 
Enzymatic 
Conversion of 
Cyanide to 
Thiocyanate 
Yes Yes 
Secondary Cyanohydrin Formation Yes No 
Quenching 
Cyanide-
Induced ROS 
Secondary 
Enzymatic 
Conversion of 
3MP to H2S 
Yes Suspected 
Secondary 
Direct 
Antioxidant 
Quenching of 
ROS 
Yes Yes 
Table	4.	Summary	of	data	for	potential	mechanisms	of	sulfanegen.	
5. Conclusions 
 The ubiquitous distribution of MST makes it an ideal target for enzyme-
catalyzed detoxification of cyanide to thiocyanate using 3MP. However, cyanide 
exposure has wide ranging effects beyond inhibition of cytochrome C oxidase.  
Cyanide induced NMDA receptor activation results in an influx of Ca2+ and an 
increase in inducible nitric oxide synthase (iNOS) activity. The resulting ROS has 
devastating downstream effects unless quenched.59 The experiments above 
demonstrate that sulfanegen is a potent antioxidant, and as a result is able to 
quench cyanide induced ROS both directly as a thiol as well as indirectly though 
enzymatic production of H2S. The work demonstrates cyanohydrin formation 
probably is not a significant contributor to cyanide antagonism for sulfanegen. 
However, sulfanegen’s MST catabolized metabolism of cyanide to thiocyanate is 
likely augmented by sulfanegen’s antioxidant properties. 
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CHAPTER V: 
MISCELLANEOUS STUDIES 	  
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1. 3MP-NEM Indicator Studies 
1.1 Introduction 	 A test to rapidly determine cyanide exposure in the field does not currently 
exist. Upon arriving at a suspected cyanide exposure, first responders must 
administer medical countermeasures before a causative agent can be 
determined. Therefore many methods for detecting and quantifying cyanide have 
been developed over the years, but most require time intensive steps, non-
aqueous solvent systems, expensive laboratory equipment, or suffer from 
selectivity issues with other anions.160,161 As a result, specific cyanide indicators 
that can be used in biological systems have been lacking. Colorimetric methods 
are particularly advantageous, as they can provide rapid detection of cyanide 
with the naked eye. Work on developing new cyanide detectors has been 
previously reviewed by Ma and Dasgupta, and the Logue laboratory has made 
recent progress on such a field-based test.161,162 Here, we report a novel cyanide 
indicator based on sulfanegen, an IM injectable, preclinical cyanide antidote that 
our lab has developed. The indicator can be quickly synthesized from sulfanegen 
using commercially available materials and works in 100% aqueous media for 
visual detection of cyanide.  
During the course of secondary mechanism elucidation studies covered in 
chapter 4, it was discovered that a solution of 3MP, after derivitization with NEM, 
produced a bright pink coloration upon treatment with a sodium cyanide solution. 
Here, we describe the characterization of the 3MP-NEM reaction with cyanide, 
and its applications to colorimetric detection of cyanide.  
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1.2 Methods 
1.2.1 Structure Activity Relationship Studies 
3MP, Cysteine, or 3-mercaptopropionic acid (100 mM) and 100 mM NEM 
in deionized water and were incubated at room temperature for 15 minutes and 
briefly mixed every 5 minutes using a VWR vortex mixer.  Then, a solution of 
NaCN was added such that final concentrations were 50 mM for both indicator 
and cyanide respectively. The resulting mixture was monitored until observation 
of a color change, or in absence of a color change, for 30 minutes. 
1.2.2 Sensitivity, Selectivity, and Specificity Studies 
To determine sensitivity of the indicator observable by the human eye, 
3MP-NEM (50 mM) and cyanide (0-50 mM) were added to 96 well plates. The 
reaction was monitored at 300, 405, and 515 nm.  
Selectivity of the indicator was examined by adding 50 mM 3MP-NEM and 
50, 100 or 500 mM sodium or potassium salts of I-, F-, NO3-, AcO-, SO4-, Cl-, 
SCN-, or CO3- to each well of a 96 well plate. The sodium or potassium 
counterions did not have a discernable effect on the assay. The reaction was 
started by addition of 50 mM NaCN and monitored at 300, 405, and 515 nm.  
Specificity studies were determined by adding 50 mM 3MP-NEM to a 96 
well plate and adding 50, 100, or 500 mM sodium, potassium, or chloride salts of 
I-, F-, NO3-, AcO-, SO4-, Cl-, SCN-, CO3-, SO32-, Br-, CLO4-, Cu2+, Mg2+, Fe2+, NH3+, 
Ca2+, PO43-, HPO42-, or H2PO4- to each well. Monitoring the reaction at 515 nm for 
30 minutes identified anions that caused an increase in absorbance without 
cyanide present.  
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1.2.3 Analytical Chemistry Analysis: Mass Spec and NMR 
3MP (50 mM) was derivitized with 50 mM NEM as described above. The 
resulting 50 mM stock solution of 3MP-NEM was diluted to 1 mM and incubated 
with an equimolar concentration of aqueous sodium cyanide at room temperature 
for 30 minutes. The final reaction volume was 1 mL. Following incubation, the 
reaction mixture was analyzed using mass spectrometry (MS) in MMI Mixed 
Negative mode, which performs electrospray and atmospheric chemical 
ionization modes simultaneously. NMR studies were carried out by Dr. Rui Ding 
in our lab. 
1.3 Results  
1.3.1 Structure Activity Relationship Studies 
 To determine if cyanohydrin formation could be the mechanism of action 
of the 3MP-NEM indicator, the α-keto acid moiety was examined by replacing 
3MP for either cysteine, in which the α-keto acid is substituted for NH2, or 3-
mercaptopropionic acid, in which the α-keto acid is removed entirely (Figure 26).  
Both modifications of the α-keto acid resulted in no color formation upon 
derivitization with NEM and addition of NaCN. Upon addition of excess hydroxide 
(OH-), 3MP-NEM turned a bright pink, while Cysteine-NEM turned faintly pink, 
and 3-mercaptopropionic-NEM remained colorless (Figure 27). However, the 
color change associated with OH- was brief, and the solution returned to 
colorless within 5 minutes. This was not the case for 3MP-NEM + NaCN, whose 
color persisted for hours.    
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Figure 26. Summary of SAR studies on α-keto acid substitutions. (1) 3MP, (2) 
Cysteine, (3) 3-mercaptopropionic acid.   
 
 
 
 
Figure 27. Representative results of SAR studies on α-keto acid substitutions. 
Only 3MP-NEM changed color upon addition of CN, while both cysteine-NEM 
and 3-mercaptopropionic-NEM (3MProp-NEM) remained colorless. 
 
Additionally, N-ethylsuccinimide was examined determine if the resulting 
structure of the NEM tag after derivitization was responsible for color formation. 
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N-ethylsuccinimide did not visibly change color upon addition of CN- or excess 
OH-, and the corresponding UV spectra were unchanged from N-
ethylsuccinimide alone.  
1.3.2 Sensitivity, Selectivity, and Specificity Studies 
Sensitivity was examined using 50 mM 3MP-NEM and 0-50 mM sodium 
cyanide. As cyanide concentration increased, pink color formation was easily 
seen by the naked eye after 2 mM and intensified with additional cyanide (Figure 
28). UV absorbance data shows a cyanide concentration dependent decrease in 
absorbance at 305 nm, and an increase in absorbance at both 410 nm and 515 
nm (Figure 30). 
Inhibitors of the indicator were examined in the presence of 50 mM 3MP-
NEM, 50 mM cyanide, and 50, 100, or 500 mM other salts. Of the potential 
inhibitors tested, high concentrations (500 mM) of nitrate (as NaNO3) and 
bicarbonate (NaHCO3) delayed the onset of color formation (Figure 28). This 
inhibition is quantified via UV absorbance at 515 nm in Figure 29. 
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Figure 28. Sulfanegen (50 mM) sensitivity to cyanide (0-50 mM) (left), and 
selectivity in the presence of common anions inhibition (right).  
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Figure 29. Quantification of inhibition by anions on cyanide indicator.  
 
	
Figure 30. Absorbance spectra changes as increasing levels of cyanide are 
added (0-50 mM).  With increasing cyanide concentration there is a dop in 
absorbance at 305 nm, and increase in absorbance at both 410 and 515 nm 
 	 From the UV/VIS absorbance specrum data, a stark difference can be 
seen between 3MP-NEM samples reacted with cyanide or base. In the cyanide 
treated samples, we see the characteristic drop at 305 nm, and increases at 410 
and 515 nm. However, in samples treated with base there is an increase at 305 
nm, no change seen at 410 nm, and an increase at 515 nm (Figure 31). The 
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increase at 515 nm in samples where NaOH was added instead of cyanide 
clears within minutes, while in the cyanide treated sample persists for hours 
(Figure 31).    	
	
Figure 31. UV absorbance spectra of the 3MP-NEM indicator. Top: Net change 
in absorbance after subracting 3MP-NEM. Bottom: 3MP-NEM in the presence or 
abense of cyanide and base. 	
 	
Selectivity studies were carried out by adding aqueous 50 mM 3MP-NEM 
and 50,100, or 500 mM salts to identify false positives. Of the non-hydroxide 
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salts tested, only phosphate (as the trisodium salt i.e. Na3PO4) showed color 
formation without the presence of cyanide (Figure 32). Fe2+ interacted with the 
3MP-NEM indicator, but the color change was a very dark green and not easily 
confused with the pink color seen in cyanide positive samples.  
 
Figure 32. Specificity studies of 3MP-NEM in presence of other ions.  
 
1.3.4 Mass-Spec Analysis 
Reactions of 3MP-NEM with either CN- or OH- were examined via mass 
spectrometry. Addition of NaCN yielded the same 3MP-NEM cyanohydrin M/Z as 
presented in Chapter 4. Adding an equimolar amount of hydroxide to 3MP-NEM 
yielded peaks corresponding to formation of a ketone hydrate at the α-keto acid 
moiety (Figure 33).  
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Figure 33. Mass Spectrometry results of the 3MP-NEM reaction with cyanide 
(top), and hydroxyl (bottom). M/Z 244 is 3MP-NEM, while M/Z 271 and M/Z 262 
correspond to resulting cyanohydrin and hydroxide addition respectively. 	
1.3.5 NMR Analysis 
Dr. Rui Ding in our lab analyzed 3MP-NEM alone, 3MP-NEM + CN-, and 
3MP-NEM + NaOH reactions via NMR. NMR results for the 3MP-NEM compound 
show that the molecule undergoes a ring closing reaction resulting from an 
intramolecular condensation of the imide enolate moiety with the ketoacid moiety 
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in solution (Figure 34). This molecule was isolated and fully characterized by Dr. 
Rui Ding. NMR data for the NaOH reaction indicates formation of many products 
that were likely the result of an aldol-type polymerization. None of these products 
were isolated and characterized. 
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Figure 34. Proposed structure of colored species observed upon addition of 
sodium cyanide (top right in red), the colored intermediate under basic conditions 
(middle in red) and the observed product that was isolated and characterized 
(bottom right). 
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1.4 Conclusions 	 Cyanide addition to 3MP-NEM produces a color shift in the visible range. 
While this indicator is useful for milimolar quantities of cyanide, sensitivity is 
insufficient for most applications, as the WHO guideline for the maximum 
concentration of cyanide in drinking water is 1.7 µM.163 The proposed mechanism 
is a reversible dehydration of the cyanohydrin that gives the resonance stabilized 
transient intermediate (Figure 35).  
 
Figure 35. 3MP-NEM cyanohydrin formation and resulting resonance structures. 
 
The colored species upon treatment with cyanide was not isolated. This 
proposed intermediate probably exists only transiently in solution, being in 
equilibrium with the more thermodynamically stable 3MP-NEM and 
corresponding cyanohydrin. Such transient intermediates or transition states are 
consistent with known mechanism of the benzoin condensation, the mass 
spectrometry data, and this scheme represents a novel cyanide indicator. 
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2. Ames Testing 
2.1 Introduction 
 As part of preliminary toxicity testing for sulfanegen, the Ames test was 
used to determine and characterize potential mutagenicity of the compound. The 
Ames test uses specific strains of Salmonella Typhimurium that have mutations 
in histidine synthesis genes. As a result of these mutations, the bacteria are 
unable to grow in media that is not supplemented with histidine. Application of a 
compound with mutagenic properties may result in a gain-of-function mutation, 
allowing the bacteria to produce their own histidine and grow in histidine free 
media.164 For these studies, both TA98 and TA100 strains of Salmonella 
Typhimurium were utilized, containing frameshift and base pair substitution 
mutations respectively.  
2.2 Methods 	
Sulfanegen was synthesized in our lab by Dr. Alexandre Monteil as 
previously described.97 The Mod-ISO 2 strain kit was purchased from EPBI 
(Ontario, CA). The directions for the kit were followed with respect to both the 
TA98 and TA100 kits using dilutions of Sulfanegen Lysine ranging from 5 mM to 
2.5 µM. The upper concentration was based on rabbit PK data, and was more 
than double the Cmax seen during those tests. The positive control for TA98 was 
4-Nitro-ortho-phenylenediamine, and for TA100 was sodium azide. After treating 
the bacteria with positive controls, various concentrations of Sulfanegen Lysine, 
or blank negative control for 48 hours, reversion wells were counted and 
compared to controls.  
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2.3 Results  
2.31 TA100 
TA100 results are summarized in Table 5. Nonreversion wells remain 
purple, while those wells that regained histidine synthesis change color from 
purple to yellow (Figure 36). No significant mutagenicity was found for any 
concentration of sulfanegen lysine examined under the reaction conditions 
described. Based on the number of reversions in the negative control, an 
average of 11 reversions per concentration are needed to have significant 
mutagenicity with significance set at p=0.05. The 5 mM concentration 
approached significance, but did not cross the threshold for base pair substitution 
mutagenicity.  
Sample Plate 1 Plate 2 Plate 3 Average 
Sterile 
Control 
0   0 
Positive 
Control 
38 36  37 
Negative 
Control 
7 4 3 4.6 
5 mM 10 8 13 10.3 
1.25 mM 6 12 9 9 
310 µM 9 3 6 6 
38.75 µM 10 7 11 9.3 
2.42 µM 8 12 8 9.3 
Table 5. Summary of Ames testing results for TA100 strain for base pair 
substitutions.  		
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Figure 36. Ames testing results for TA98 strain. Reversion wells are yellow while 
non-reversion wells remain purple.  
2.32 TA98 
The results for TA98 are summarized in Table 6. No significant 
mutagenicity was found for any concentration of sulfanegen lysine examined 
under the reaction conditions described. Based on the number of reversions in 
the negative control, an average of more than 7 reversions would be needed in 
order to have significant mutagenicity at p = 0.05. 
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Sample	 	Plate	1	 Plate	2	 Plate	3		 Average	
Sterile	
Control	
0	 	 	 0	
Positive	
Control	
41	 40	 	 40.5	
Negative	
Control	
3	 4	 0	 2.33	
5	mM	 2	 4	 6	 4	
1.25	mM	 0	 2	 0	 0.666	
310	µM	 10	 2	 1	 4.3	
38.75	µM	 3	 4	 4	 3.66	
2.42	µM	 0	 0	 2	 0.666	
Table 6. Summary of Ames testing results for TA98 strain for frameshift 
substitutions.  	
2.4 Conclusions 
Sulfanegen Lysine formulation was not found to be significantly mutagenic 
at any dose tested. Doses were as biologically relevant as possible by doubling 
the Cmax seen in rabbit studies as the max dose. Ames testing is only a small part 
of the battery of toxicological testing required to demonstrate safety for drug 
approval, but these preliminary results, which will need to one day be completed 
under good laboratory practice (GLP) conditions, are promising at the biologically 
relevant doses tested. High levels of mutagenicity were not expected, as all 
components of the proprietary formulation are endogenous.  
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3. Non-Enzymatic Oral Antidotes  
3.1 Introduction 
Cyanide intoxication can occur by multiple of routes of administration. 
Inhalation of HCN gas is one of the most dangerous, with death occurring within 
minutes. Oral ingestion of cyanide leads to a slower onset of toxicity, and this lag 
may present an opportunity for chemical countermeasure administration. Oral 
antidotes have not received much attention, as it is believed that most cyanide is 
converted into HCN upon reaching the gastric stomach acids. HCN is 
electrostatically neutral, and as a result is able to freely pass through cellular 
membranes. However, the stomach pH is not static, and variations may allow 
time for oral antidotes to detoxify cyanide before it is able to show effects 
systemically. Here we present the results of proof of concept studies designed at 
testing the efficacy of non-enzymatic trisulfide antidotes to detoxify cyanide into 
thiocyanate in acidic environments.  
3.2 Methods 
3.2.1 Chemicals 
Trisulfide compounds for potential antidotes were synthesized by Dr. 
Johnathan Cohen in our laboratory. Cysteine-S-Cysteine (Cys-S-Cys) and 
Glutathione-S-Glutathione (GS-S-SG). 
3.2.2	Non-Enzymatic	Thiocyanate	Production	
Safety warning: 
Beware of working with cyanide in acidic environments. Take proper 
safety precautions and work in a fume hood. Neutralize reactions with excess 
bleach after assay completion in to prevent further toxic HCN gas formation. 
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Thiocyanate production was measured using the same methods as in 
MST thiocyanate production studies (Chapter 2), i.e. by addition of ferric nitrate 
and UV absorption as previously described.118,165 In short, 15 mM Cys-S-Cys or 
GS-S-SG was prepared in 450 µL 0.01M HCL (pH 2.0) in a micro-centrifuge 
tube. HCN (50 µL, 500 mM) was added to the reaction, and the vial immediately 
capped. After 10 minutes, the vial was opened, 500 µL ferric nitrate was added to 
the solution and a 20 µL aliquot was diluted to 200 µL. The vial was then 
immediately closed. Absorbance was read at 450 nm.  
3.2.3	Kinetics	
Kinetics of the reaction were monitored using the assay above, except 
total reaction volumes were increased to 1000 µL. Every 2 minutes for 40 
minutes, a 50 µL aliquot of the reaction is mixed with 50 µL ferric nitrate solution 
and absorption read at 450 µL. Results were confirmed with multi-vial kinetic 
reactions designed to prevent overall cyanide concentration decreasing via HCN 
gas leaking from multiple openings of the reaction vial.  
3.3 Results  
Non-enzymatic trisulfide antidotes were successful at producing 
thiocyanate in the 10 minutes allotted for the reaction time (Figure 37). However, 
reaction yield was poor, as Cys-S-Cys and GS-S-SG produced only 750 µM (5%) 
and 370 µm (2.5%) thiocyanate respectively. Following these results, Cys-S-Cys 
reaction kinetics were more closely examined. Using 2.2 mM Cys-S-Cys and a 
reaction time of 40 minutes, thiocyanate production ceased after only 4 minutes 
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to 120 µM thiocyanate, representing once again ~5% total SCN production 
(Figure 38).   
 
Figure 37. Representative thiocyanate production of trisulfate antidotes. Darker 
solution equals more thiocyanate produced. CYS = Cys-S-Cys GSH= GS-S-SG 
 
 
Figure 38. Cys-S-Cys multivial reaction kinetics. Thiosulfate reached its maximal 
concentration at around 6 minutes after reagents were mixed, with a 5% yield.  
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3.4 Conclusions 
Although the trisulfide antidotes were capable of detoxifying cyanide by 
conversion into thiocyanate non-enzymatically, the small reaction yields prevent 
application to oral cyanide toxic exposure. In these instances, patients would 
likely have better outcomes if either of the currently approved therapies were 
administered. It is possible thiocyanate production could be improved if the pH of 
the reaction conditions were neutralized, but those experiments were outside of 
the scope of the current investigation. It is unknown to what extent low SCN 
yields were due to outgassing of HCN, though the tests were performed in closed 
vessels, HCN could have accumulated in the headspace above the reaction 
volume. Further pursuit of trisulfide oral antidotes was abandoned, as outgassing 
would also occur in the stomach, limiting utility.  
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4. Expanding the Scope of Diseases – Obliterative Bronchiolitis and 
Thioredoxin Mimetics  
4.1 Introduction 
Obliterative bronchiolitis (OB) is a rare condition that results in progressive 
and irreversible airway restriction.166 OB is most commonly seen in lung 
transplant patients, where the disease is often deadly. OB is responsible for up to 
40% of patient deaths after the first year in lung transplant patients, and affects 
up to 50% of patients who survive at least 5 years post transplant.167 The exact 
cause of OB has not been delineated, but fibroblasts, lymphocytes, and graft 
antibodies have all been implicated.166,168–172 Ultimately, some unknown 
upstream trigger of epithelial injury leads to an antibody and lymphocyte immune 
response, whose oxidative damage and inflammation causes progressive fibrosis 
and airflow limitations.166  
The antioxidant capability of sulfanegen, which was characterized in 
Chapter IV, was tested in OB with mild efficacy. Lack of a robust response to halt 
progression of the disease in animal models is likely due to sulfanegen’s 
pharmacokinetic (PK) properties, previously studied in rabbits.122 Sulfanegen’s 
short half-life of 114 minutes (in the absence of cyanide) is adequate for acute 
poisonings, but likely insufficient for chronic conditions like OB without frequent 
administration. With proof-of-concept studies for antioxidant efficacy in OB 
demonstrating potential benefits, Dr. Marzena Bahran in our lab performed 
synthesis of thioredoxin mimetics as potential antioxidants with the goal of 
increasing half-lives. 
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Thioredoxins (TRX) are a ubiquitous class of protein that play roles in 
maintaining the cellular redox state.173 The mechanism of their antioxidant 
capability stems from their cysteine-x-x-cysteine structure, where “X” represents 
an amino acid. Close proximity of the cysteine residues permit reduction of 
oxidized proteins, forming cys-cys disulfide bonds.173–175 Oxidized thioredoxin is 
then reduced by thioredoxin reductase (TRXR), which is regenerated by 
reduction via NADPH (Figure 39). 173–175 
 
Figure 39. Thioredoxin reaction scheme. Thiorexoxin (Trx) alleviates cellular 
oxidative damage by forming a disulfide. Trx is reduced by thioredoxin reductase 
(TrxR), which is regenerated by NADPH.  
 
Cyclophosphamide, a chemotherapeutic and immune suppressant, is 
often administered following organ transplantation to prevent rejection. 
Cyclophosphamide administration leads to DNA alkylation and oxidative 
stress.176,177 Cyclophosphamide is converted into its active metabolite 4-
hydroxycyclophosphamide (4HC) by cytochrome P450 2B1.177 4HC then 
spontaneously breaks down into phosphoramide mustard, which alkylates the 
guanine residue of DNA, forming cross-links.177,178 The oxidative cell damage 
4HC causes is especially concerning in lung transplant patients, who are already 
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at increased risk of fibrosis and OB. Therefore, it is hypothesized that thioredoxin 
mimetics will be able to ameliorate 4HC induced oxidative stress in human 
bronchial epithelial cells (HBECs).   
4.2 Methods 
4.2.1 Chemicals 
Prodrug thioredoxin mimetics (the oligopeptides MB-11, MB-13, and MB-
16) were synthesized by Dr. Marzena Bahran. 4HC was purchased from Toronto 
Research Chemicals (Toronto, ON) DCFH-DA was purchased from Abcam 
(Cambridge, UK). 
4.2.2 Cell Culture 
Immortalized human bronchial epithelial cells (HBEC) were grown to 80% 
confluency in bronchial epithelial growth medium (BEGM). Confluent cells were 
plated in 96 well plates at 15,000 cells / well and incubated overnight before 
assaying.  
To examine thioredoxin mimetic efficacy on quenching 4HC induced ROS, 
the DCFH-DA assay was employed. After overnight incubation, the cells were 
washed in PBS and 0-400 µM MB-11, MB-13, MB-16, or NAC were added to 
HBEC cells and incubated for 0, 6, or 18 hours. Media containing the compound 
of interest were collected 30 minutes prior to the end of incubation, cells were 
washed in PBS, and 100 µM DCFH-DA was added for 30 minutes. Following the 
DCFH-DA incubation, cells were re-washed with PBS and media containing the 
compounds of interest were re-added. 50 µM 4HC was then added, and 
florescence was monitored at 485em/530ex for 2 hours. 
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Cytotoxicity studies were carried out using a Vybrant cytotoxicity assay kit 
(Molecular Probes, Eugene OR) by measuring glucose-6-phosphate (G6P) 
leakage. After 15,000 cells / well were plated overnight, 0-400 µM MB-11, MB-13, 
or MB-16 were added to the wells and incubated for 18 hours. Protocol for the kit 
was then followed and absorbance was read at 560em/590ex for 30 minutes. 
Detergent was added to the positive control wells to lyse the cell membranes, 
yielding the total amount of G6P in the wells.  
4.3 Results  
4.3.1 DCFH-DA Assay 
Without pre-incubation of the thioredoxin mimetics before 4HC addition, 
the test compounds were. However, pre-incubating the thioredoxin mimetics for 
either 6 or 18 hours showed interesting results. At 6 hours, 200 µM of MB-11, 
MB-13, and MB-16 were approximately equipotent to 200 µM NAC at quenching 
4HC-induced ROS (Figure 40). MB-11, MB-13, MB-16, and NAC all decreased 
relative florescence to around 60% at the 200 µM concentration.  
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Figure 40. Thioredoxin mimetic efficacy in HBEC after 6 hour pre-incubation. 
Positive control is 200 µM NAC. 	
This trend of increasing efficacy with longer pre-incubation times when 
compared to NAC continued at the 18 hour preincubation time point for all 
compounds tested. NAC (200 µM) efficacy remained the same, decreasing 
relative florescence once again to around 60%, but MB-11, MB-13, and MB-16 
outperformed NAC at these longer incubation times. NAC (200 µM) was roughly 
equivalent to the 100 µM thiorexodin mimetic concentrations (Figure 41). 
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Figure 41. Thioredoxin mimetic efficacy in HBEC after 18 hour pre-incubation. 
Positive control is 200 µM NAC. 	
4.3.2 Cytotoxicity Assay 
Cytotoxicity of the thioredoxin mimetics was determined by measuring 
glucose-6-phosphate leakage from the cellular membrane. Concentrations from 
the DCFH-DA efficacy assay were doubled (0-400 µM) and incubated for 18 
hours. No significant toxicity (representing more than a 5% increase in cellular 
death) was seen (Figure 42).  
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Figure 42. Cytotoxicity of thioredoxin mimetics as measured by G6P leakage. 
NAC was 400 µM, and positive control represents 100% G6P leakage.  	
4.4 Conclusions 
The thioredoxin mimetics MB-11, MB-13, and MB-16 were ineffective 
when added concurrently with 4HC, yet all showed efficacy after preincubation 
with HBEC cells. This preincubation was likely required to allow the deacetylation 
of the prodrug compounds into their active form. Additionally, the compounds did 
not show significant cytotoxicity at the concentrations tested. At this time, it is not 
known if MB-11, MB-13, or MB-16 are substrates for thioredoxin reductase. 
Elucidation of this potential mechanism of action will be carried out in due course 
along with studies to confirm disease modification in transplant animals. 
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The IM route of administration of sulfanegen is well suited for mass-
casualty cyanide exposure scenarios. Studies in murine, pig, and rabbit models 
of cyanide toxicity demonstrate suflanegen’s efficacy at detoxifying cyanide. 
However, the FDA’s “Animal Rule” necessitates additional conditions be met for 
approval because ethical concerns prevent efficacy evaluation in humans.  The 
focus of this dissertation is elucidation of sulfanegen’s mechanism as a cyanide 
antidote and addressing the additional hurdles to clinical translation resulting 
from the animal rule.   
 Chapter 1 reports both a blood and tissue-specific MST species 
comparison to demonstrate which animal models of cyanide toxicity are most 
appropriate for predicting human efficacy. Murine and rabbit models flanked 
humans for MST specific activity and thus, when combined, represent 
reasonable models of human activity. In our judgment, these species should 
suffice as reasonable models of efficacy for humans. An unexpected finding from 
this study was the difference in MST specific activity that smoking status had in 
human liver samples. Smokers had statistically significant higher MST specific 
activities in the liver mitochondria than their non-smoking counterparts. Increased 
activity could be an adaptation to chronic, low-level cyanide exposure found in 
cigarette smoke and indicate that mitochondrial MST may be inducible in 
humans. Although we only addressed MST location and activity here, these data 
should be consolidated with thiocyanate elimination data to more strongly justify 
their choice as species for MST efficacy. Comparative thiocyanate elimination 
kinetics will be addressed in due course. 
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 Chapter 2 reports a UV HPLC method suitable for detecting 3MP, with 
applications to both quality control and biological quantification. UV detection 
makes the analysis readily amenable to most laboratories, without the need for 
specialized detection methods. Previous pharmacokinetic studies by the Logue 
and Patterson labs yielded a Cmax of 1775 µM 3MP in rabbits, and if 
concentrations of 3MP are similar following administration in humans, samples 
require minimal dilution for analysis. Previously, quality control methods were 
unavailable.  
 Chapter 3 reports the possible secondary mechanisms of sulfanegen 
administration, both in the presence and absence of MST. Sulfanegen showed 
biologically relevant efficacy as an antioxidant. As a reducing thiol, sulfanegen 
can quench cyanide induced ROS without a catalyst. Moreover, in the presence 
of MST sulfanegen administration leads to the production of H2S, which can also 
quench cyanide induced ROS. Finally, we examined sulfanegen’s ability to 
directly detoxify cyanide by forming a cyanohydrin. However, even though this 
mechanism was detectable via mass spectrometry, in the absence of MST 
sulfanegen was ineffective in reversing cyanide-induced inhibition of cytochrome 
C oxidase. We therefore conclude cyanohydrin formation is probably not 
therapeutically relevant for this drug candidate, although sulfanegen’s antioxidant 
actions as a thiol and MST-mediated H2S generation contribute to overall 
efficacy.   
In addition to the IM route of administration, sulfanegen has previously 
shown efficacy when administered orally. Therefore, future directions for this 
	 101	
project could include an oral sulfanegen formulation for preventing acute or 
chronic cyanide toxicity in cases of either contaminated food or drinking water. 
Moreover, Konzo, a debilitating paralysis condition resulting from chronic, low 
dose cyanide exposure, may be preventable by taking sulfanegen 
prophylactically. Additionally, oral sulfanegen could have veterinary applications 
as a food additive protecting livestock from cyanogenic glycosides in the field.  
 Further studies required for clinical translation of sulfanegen as an IM 
injectable antidote include: A battery of GLP safety studies, including 
mutagenicity, reproductive and development toxicity, definitive efficacy studies in 
justified animal models as well as an extended phase 1 safety study in humans. 
The work covered in this dissertation establishes groundwork that should enable 
studies carried out in GLP laboratory conditions, both for safety evaluations, 
mutagenicity and definitive animal models under the animal rule. In addition, 
these studies here should help satisfy the FDA requirement for reasonable 
attempts to elucidate the mechanism of action for sulfanegen. 
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